

Competing-risk Weibull survival model with multiple causes

Kai Wang^{a,b}, Yuqin Mu^{a,b}, Shenyi Zhang^a, Zhengjun Zhang^{c,d}, and Chengxiu Ling^{*,a}

^aAcademy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou, 215123, China

^bDepartment of Mathematical Sciences, University of Liverpool, Liverpool, L693BX, UK

^cDepartment of Statistics, School of Computer, Data & Information Sciences, University of Wisconsin, Madison, WI 53706, USA

^dSchool of Economics and Management, University of Chinese Academy of Sciences, Beijing, 101418, China

*Corresponding author

August 2024

Abstract

The failure of a system can result from the simultaneous effects of multiple causes, where assigning a specific cause may be inappropriate or unavailable. Examples include contributing causes of death in epidemiology and the aetiology of neurodegenerative diseases like Alzheimer's. We propose a parametric Weibull accelerated failure time model for multiple causes, incorporating a data-driven, individualized, and time-varying winning probability (relative importance) matrix. Using maximum likelihood estimation and the expectation-maximization (EM) algorithm, our approach enables simultaneous estimation of regression coefficients and relative cause importance, ensuring consistency and asymptotic normality. A simulation study and an application to Alzheimer's disease demonstrate its effectiveness in addressing cause-mixture problems and identifying informative biomarker combinations, with comparisons to Weibull and Cox proportional hazards models.

1 Introduction

Competing risks are inherent features of survival analysis. A patient's death or hospitalization may result from known diseases (e.g., cancers, chronic or infectious diseases), unidentified genetic factors, or non-disease-related influences such as ageing and climate change. Traditional cause-specific and subdistribution models are well-established based on identified particular causes of the events. However, as populations age with chronic and degenerative diseases becoming the primary causes of mortality, the necessity to account for multiple

causes or multiple potential risks for a specific event (e.g., death due to comorbidities) is growing. Recent epidemiological studies on mortality and disease burden increasingly consider all contributing causes of death recorded on death certificates rather than focusing solely on the underlying cause (Li et al., 2022; Moreno-Betancur et al., 2017). Meanwhile, the aetiology of high-burden neurodegenerative diseases, such as Alzheimer’s (Burns and Iliffe, 2009) and Parkinson’s (Morris et al., 2024), remains poorly understood, with definitive causes of disease progression yet to be identified. This leads to increasing interest in investigating potential genetic and environmental risk factors, to better understand disease mechanisms and inform prevention strategies.

Multiple causes of events are conceptually similar to unknown or missing causes in the statistical literature, which are typically addressed using inverse probability weighting (IPW) (Goetghebeur and Ryan, 1995) and multiple imputation (MI) methods (Lu and Tsiatis, 2001). More recently, Moreno-Betancur and Latouche (2013) extended the Andersen–Klein pseudo-value approach, grounded on IPW and MI. Mao and Lin (2017) adapted the subdistribution model (Fine & Gray model) to assess covariate effects for all causes and accommodate cases of some missing causes. For situations of entirely unknown causes, Moreno-Betancur et al. (2017) proposed a disease mixture model, where all contributing causes are modelled via cause-specific hazards and contribute to the death process with predetermined probability weights. This approach gained rising attention and widely applied in mortality risk analyses, including worldwide studies on HIV-positive patients (Breger et al., 2020), gastric adenocarcinoma patients (Xie et al., 2020), post-lung transplantation patients (Anderson et al., 2023), and all-cause mortality (Bishop et al., 2023; Dobson et al., 2023; Wijnen et al., 2022).

In this paper, we propose a competing Weibull survival model for multiple causes, where covariates are modelled linearly for the latent Weibull survival times of contributing risks (competing factors), and the event time is determined by the minimum of these latent times. Our model enables simultaneous estimation of covariate effects and a data-driven winning probability matrix (relative importance matrix), meeting all three key criteria in

Moreno-Betancur et al. (2017): (1) each competing factor accounts for each contributing cause; (2) only the observed event time is required, and each event is counted only once; and (3) the winning probability matrix dynamically captures the individualized and time-varying relative importance of all contributing causes, without requiring prior knowledge or preliminary analysis in methods with predetermined weights. Furthermore, as an extension of the Weibull accelerated failure time model to the max-linear family (Cui et al., 2021; Cui and Zhang, 2018; Zhang, 2021), our approach encompasses simple Weibull survival models as a special case, enabling the modelling of non-Weibull survival times via Weibull errors, and maintaining the interpretability. It also facilitates the incorporation of penalization for model sparsity, which is useful for identifying key risk factors among numerous potential options in neurodegenerative diseases.

The rest of this paper is organized as follows. In Section 2, we introduce the competing Weibull survival model. In Section 3, we apply the Expectation-Maximization (EM) algorithm for maximum likelihood estimation and present the asymptotic results, followed by the penalization framework for model sparsity and unbiased prediction estimator. In Section 4, we conduct simulation studies to compare the performance of the proposed models with the simple Weibull model and Cox model. We then provide a real data application for Alzheimer’s disease progression using data from Alzheimer’s Disease Neuroimaging Initiative (ADNI) in Section 5 and make some concluding remarks in Section 6. All technical proofs and lemmas are provided in the Appendix.

2 Model Specification

Consider the Weibull survival time $T \sim \text{Weibull}(\kappa, \lambda)$ with survival distribution $S(t) = \exp(-(t/\lambda)^\kappa)$, $t > 0$, with scale parameter $\lambda > 0$ and shape parameter $\kappa > 0$, leading thus to the location-scale form of

$$\tilde{T} \stackrel{d}{=} \log T = \mu + \sigma\epsilon, \quad \mu = \log \lambda \in \mathbb{R}, \quad \sigma = 1/\kappa,$$

with the error $\epsilon \sim \Lambda(x) = 1 - \exp(-e^x)$, $x \in \mathbb{R}$, the Gumbel distribution for the minima. Here $\stackrel{d}{=}$ stands for equality in distribution.

For the competing Weibull case, assuming the survival time T (under competing) is the min-linearly associated with L competing risks, the model is then specified as

$$\log T \stackrel{d}{=} \min(\alpha_1 + \mathbf{x}_1^\top \boldsymbol{\beta}_1 + \sigma_1 \epsilon_1, \dots, \alpha_L + \mathbf{x}_L^\top \boldsymbol{\beta}_L + \sigma_L \epsilon_L), \quad (2.1)$$

where ϵ_l , $l = 1, 2, \dots, L$ are independent and identically distributed errors with common distribution Λ , and $\mathbf{x}_l = (x_j, j \in A_l)$ is a p_l -dimensional vector of candidate predictor matrix $\mathbf{x} = (\mathbf{x}_1, \dots, \mathbf{x}_p)$ with $A_l \subset \{1, 2, \dots, p\}$ with $|A_l| = p_l \in [1, p]$. The predictor matrix may have overlapping columns but should not be completely identical, otherwise unidentifiability will be introduced. The intercepts $\alpha_1, \dots, \alpha_L$ control the relative importance of each risk, where a very large intercept indicates an approximately eliminated risk with the min-competing structure. Then, the survival probability of T becomes

$$\begin{aligned} \mathbb{P}\{T > t\} &= \mathbb{P}\{\log T > \log t\} = \prod_{1 \leq l \leq L} \mathbb{P}\left\{\epsilon_l > \frac{\log t - \mu_l}{\sigma_l}\right\} \\ &= \exp\left(-\sum_{1 \leq l \leq L} t^{1/\sigma_l} \exp\left(-\frac{\mu_l}{\sigma_l}\right)\right) = \exp\left(-\sum_{1 \leq l \leq L} \left(\frac{t}{\lambda_l}\right)^{\kappa_l}\right) \\ &= \prod_{1 \leq l \leq L} \mathbb{P}\{T_l > t\} = \mathbb{P}\left\{\min_{1 \leq l \leq L} T_l > t\right\}, \end{aligned} \quad (2.2)$$

where T_l , $l = 1, 2, \dots, L$ are the potential survival times for competing risks (diseases), which are mutually independent and following Weibull(λ_l, κ_l) with

$$\log \lambda_l = \mu_l = \alpha_l + \mathbf{x}_l^\top \boldsymbol{\beta}_l, \quad \sigma_l = 1/\kappa_l, \quad l = 1, 2, \dots, L.$$

Therefore, the density, hazard and survival function of T satisfy the following equations

$$\begin{aligned} f(t) &= -\frac{dS(t)}{dt} = S(t) \sum_{1 \leq l \leq L} \frac{\kappa_l t^{\kappa_l - 1}}{\lambda_l^{\kappa_l}}, \quad \log S(t) = \sum_{l=1}^L \log S_l(t) \\ h(t) &= \frac{f(t)}{S(t)} = \sum_{1 \leq l \leq L} \frac{\kappa_l t^{\kappa_l - 1}}{\lambda_l^{\kappa_l}} =: \sum_{1 \leq l \leq L} h_l(t). \end{aligned} \quad (2.3)$$

Motivated by the max-linear relationships discussed in [Cui et al. \(2021\)](#); [Cui and Zhang \(2018\)](#); [Zhang \(2021\)](#), our competing Weibull model is designed with linear relations within groups and nonlinear (min) relations between groups. Each risk is modelled as a linear function of predictors, providing a structure that enhances interpretability. The survival time T can also be conceptualized as the minimum of survival times associated with L distinct diseases, reflecting a natural competing risks framework. By assuming mutual independence among the risks, the model enables the construction of a complete likelihood function. Furthermore, the winning probability for each competing factor (disease) at any time t , denoted as $\eta_l(t)$, can be explicitly calculated, as detailed in [Section 3](#). In summary, this formulation facilitates interpretability while addressing the complexity of competing risks and provides a data-driven approach to capturing the relative importance of each risk.

3 Estimation and Prediction

3.1 Estimation via EM algorithm

We consider the random censoring case with data $(T_i, \delta_i, \mathbf{X}_i)$, $i = 1, \dots, n$ and $\delta_i = \mathbb{I}(T_i < C_i)$, the non-censoring indicator function. In the following, we will develop the EM algorithm to find the maximum likelihood estimation (MLE) of the parameters involved, denoted as

$$\boldsymbol{\theta} = (\alpha_1, \boldsymbol{\beta}_1, \sigma_1, \dots, \alpha_L, \boldsymbol{\beta}_L, \sigma_L).$$

The Weibull survival likelihood function is given by

$$\begin{aligned} L(\boldsymbol{\theta}) &= \prod_{i=1}^n f(t_i; \boldsymbol{\theta}, \mathbf{X}_i)^{\delta_i} S(t_i; \boldsymbol{\theta}, \mathbf{X}_i)^{1-\delta_i} = \prod_{i=1}^n h(t_i; \boldsymbol{\theta}, \mathbf{X}_i)^{\delta_i} S(t_i; \boldsymbol{\theta}, \mathbf{X}_i) \\ &= \prod_{i=1}^n \left(\sum_{1 \leq l \leq L} \frac{t_i^{1/\sigma_l - 1}}{\sigma_l \exp((\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right)^{\delta_i} \exp \left(- \sum_{1 \leq l \leq L} \left(\frac{t_i}{\exp(\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l} \right), \end{aligned}$$

leading thus to the log-likelihood

$$\ell(\boldsymbol{\theta}) = \log L(\boldsymbol{\theta}) = \sum_{i=1}^n \delta_i \log \left(\sum_{l=1}^L \frac{t_i^{1/\sigma_l - 1}}{\sigma_l \exp((\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right) - \sum_{l=1}^L \left(\frac{t_i}{\exp(\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l},$$

which is differentiable with respect to $\boldsymbol{\theta}$. One may directly apply for numerical analysis to obtain the MLE of $\boldsymbol{\theta}$.

Next, we develop an EM algorithm to optimize the group-wise likelihoods of $\boldsymbol{\theta}_l = (\alpha_l, \boldsymbol{\beta}_l, \sigma_l)^\top$, $l = 1, 2, \dots, L$ for each of L competing factors. Recall that when maximizing the observed likelihood directly with parameter θ and data \mathbf{y} is complicated, the EM algorithm (Dempster et al., 1977) provides an effective alternative by introducing augmented data \mathbf{k} . The log-likelihood can then be expressed as

$$\log L(\theta|\mathbf{y}) = \mathbb{E} \{ \log L_C(\theta|\mathbf{y}, \mathbf{k}) \} - \mathbb{E} \{ \log p(\mathbf{k}|\theta, \mathbf{y}) \},$$

where the expectation is taken with respect to $p(\mathbf{k}|\theta_0, \mathbf{y})$ with true parameter θ_0 . Here, $p(\mathbf{k}|\theta, \mathbf{y}) = p(\mathbf{y}, \mathbf{k}|\theta)/p(\mathbf{y}|\theta)$. Denoting $\mathbb{E} \{ \log L_C(\theta|\mathbf{y}, \mathbf{k}) \}$ by $Q(\theta|\theta_0)$, the algorithm iteratively increases $Q(\theta|\theta_0)$, as $\mathbb{E} \{ \log p(\mathbf{k}|\theta, \mathbf{y}) \}$ naturally decreases by Jensen's inequality when $p(\mathbf{k}|\theta, \mathbf{y}) \neq p(\mathbf{k}|\theta_0, \mathbf{y})$.

To this, we introduce an augmented variable K , denoting the dominating group for the uncensored samples, the complete likelihood for (T, K) is

$$L_C(\boldsymbol{\theta}) = \prod_{i=1}^n \left(\prod_{l=1}^L f(T_i, K_i = l)^{\mathbb{I}(K_i=l)} \right)^{\delta_i} S(T_i)^{1-\delta_i}. \quad (3.1)$$

Noting the explicit form of survival function $S(t)$ specified in Eq.(2.2), we will show first

$$f(t, K = l) = \frac{t^{1/\sigma_l - 1}}{\sigma_l \exp(\mu_l/\sigma_l)} \exp\left(-\sum_{1 \leq k \leq L} \left(\frac{t}{\exp(\mu_k)}\right)^{1/\sigma_k}\right) = h_l(t)S(t). \quad (3.2)$$

It follows that $K = l$ is equivalent to $\log T = \mu_l + \sigma_l \epsilon_l$. We have the joint survival distribution of (T, K) given as

$$\begin{aligned} \mathbb{P}\{T > t, K = l\} &= \mathbb{P}\{\log T > \log t, K = l\} \\ &= \mathbb{P}\{\mu_k + \sigma_k \epsilon_k > \mu_l + \sigma_l \epsilon_l > \log t, \forall k \neq l\} \\ &= \int_{z > t} \prod_{k \neq l} \mathbb{P}\{\mu_k + \sigma_k \epsilon_k > \log z\} d\mathbb{P}\{\mu_l + \sigma_l \epsilon_l \leq \log z\} \text{ by the total law of probability} \\ &= \int_t^\infty \frac{z^{1/\sigma_l - 1}}{\sigma_l \exp(\mu_l/\sigma_l)} \exp\left(-\sum_{1 \leq k \leq L} \left(\frac{z}{\exp(\mu_k)}\right)^{1/\sigma_k}\right) dz, \quad t > 0, \end{aligned}$$

where the last step follows by the fact that $\epsilon_l \stackrel{i.i.d.}{\sim} \Lambda(x) = 1 - \exp(-e^x)$, $x \in \mathbb{R}$. Consequently, Eq.(3.2) follows from Eqs.(2.2) and (2.3).

Combining Eqs.(2.2), (3.1), and (3.2), it is ready to give the complete log-likelihood function

$$\begin{aligned} \ell_C(\boldsymbol{\theta}) &= \sum_{i=1}^n \delta_i \sum_{l=1}^L \mathbb{I}(K_i = l) \log f(T_i, K_i = l) + \sum_{i=1}^n (1 - \delta_i) \log S(T_i) \\ &= \sum_{i=1}^n \delta_i \sum_{l=1}^L \mathbb{I}(K_i = l) \left[\left(\frac{1}{\sigma_l} - 1\right) \log T_i - \log \sigma_l - \frac{\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l}{\sigma_l} - \sum_{k=1}^L \left(\frac{T_i}{\exp(\alpha_k + \mathbf{X}_{ik}^\top \boldsymbol{\beta}_k)}\right)^{1/\sigma_k} \right] \\ &\quad - \sum_{i=1}^n (1 - \delta_i) \sum_{l=1}^L \left(\frac{T_i}{\exp(\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l)}\right)^{1/\sigma_l}. \end{aligned}$$

The conditional probability of K given t , interpreted as the winning probability of group l ,

is expressed as

$$\eta_l(t) = \mathbb{P}\{K = l|t\} = \frac{f(t, K = l)}{f(t)} = \frac{\frac{t^{1/\sigma_l - 1}}{\sigma_l \exp(\mu_l/\sigma_l)}}{\sum_{k=1}^L \frac{t^{1/\sigma_k - 1}}{\sigma_k \exp(\mu_k)}} = \frac{\frac{t^{1/\sigma_l}}{\sigma_l \exp(\mu_l/\sigma_l)}}{\sum_{k=1}^L \frac{t^{1/\sigma_k}}{\sigma_k \exp(\mu_k)}},$$

which leads to the analytical form of the $Q(\boldsymbol{\theta}|\boldsymbol{\theta}^{(m)})$ in the E-step for the EM algorithm, where $\boldsymbol{\theta}^{(m)}$ is the estimated $\boldsymbol{\theta}$ at step m (the same for $\eta_{il}^{(m)}$):

$$\begin{aligned} Q(\boldsymbol{\theta}|\boldsymbol{\theta}^{(m)}) &= \sum_{i=1}^n \sum_{l=1}^L \delta_i \eta_{il}^{(m)} \left[\left(\frac{1}{\sigma_l} - 1 \right) \log T_i - \log \sigma_l - \frac{\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l}{\sigma_l} - \sum_{k=1}^L \left(\frac{T_i}{\exp(\alpha_k + \mathbf{X}_{ik}^\top \boldsymbol{\beta}_k)} \right)^{1/\sigma_k} \right] \\ &\quad + \sum_{i=1}^n \sum_{l=1}^L (\delta_i - 1) \left(\frac{T_i}{\exp(\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l} \\ &= \sum_{i=1}^n \sum_{l=1}^L \delta_i \eta_{il}^{(m)} \left[\left(\frac{1}{\sigma_l} - 1 \right) \log T_i - \log \sigma_l - \frac{\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l}{\sigma_l} \right] - \left(\frac{T_i}{\exp(\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l}. \end{aligned}$$

Clearly, we can rewrite the Q function above as the sum of groupwise Q_l functions below

$$\begin{aligned} Q_l(\boldsymbol{\theta}|\boldsymbol{\theta}^{(m)}) &:= \sum_{i=1}^n \delta_i \eta_{il}^{(m)} \left[\left(\frac{1}{\sigma_l} - 1 \right) \log T_i - \log \sigma_l - \frac{\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l}{\sigma_l} \right] - \left(\frac{T_i}{\exp(\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l} \\ &= \sum_{i=1}^n \delta_i \left[\eta_{il}^{(m)} \left(\frac{1}{\sigma_l} - 1 \right) \log T_i - \eta_{il}^{(m)} \log \sigma_l - \eta_{il}^{(m)} \frac{\mu_{il}}{\sigma_l} \right] - \left(\frac{T_i}{\exp(\mu_{il})} \right)^{1/\sigma_l}. \end{aligned}$$

The optimization of the M-step given η_{il} can be separated into L optimization problems by the groups since the parameters $\boldsymbol{\theta}_l = (\alpha_l, \boldsymbol{\beta}_l, \sigma_l)^\top$ only appear in $Q_l(\boldsymbol{\theta}|\boldsymbol{\theta}^{(m)})$. This property facilitates the group-wise optimization at M-step. The EM algorithm iterates between the E-step that updates the winning probability of each factor, and the M-step that maximizes the group-wise conditional expectation of the complete log-likelihood function. The subject function of Q_l is not concave in parameters, the EM algorithm is supposed to still be applicable by gradient descent in $Q_l(\boldsymbol{\theta}|\boldsymbol{\theta}^{(m)})$, but there are no guarantees for a global maximum.

The group-wise partial derivatives with respect to (w.r.t.) μ_{il} and σ_l are

$$\begin{aligned}\frac{\partial Q_l(\boldsymbol{\theta}|\boldsymbol{\theta}^{(m)})}{\partial \mu_{il}} &= \frac{1}{\sigma_l} \sum_{i=1}^n \left[\left(\frac{T_i}{\exp(\mu_{il})} \right)^{1/\sigma_l} - \delta_i \eta_{il}^{(m)} \right], \\ \frac{\partial Q_l(\boldsymbol{\theta}|\boldsymbol{\theta}^{(m)})}{\partial \sigma_l} &= \frac{1}{\sigma_l^2} \sum_{i=1}^n \delta_i \eta_{il}^{(m)} (\mu_{il} - \sigma_l - \log T_i) + (\log T_i - \mu_{il}) \left(\frac{T_i}{\exp(\mu_{il})} \right)^{1/\sigma_l},\end{aligned}\quad (3.3)$$

which are modified with penalization terms to ensure regularization and stability during gradient descent in practical implementation.

3.2 Penalization

In this section, we introduce sparsity by incorporating the lasso-type penalization with tuning parameters λ_1 and λ_2 ,

$$\min_{\boldsymbol{\theta}} -L(\boldsymbol{\theta}) + \sum_{l=1}^L [\lambda_1 e^{-\alpha_l} + \lambda_2 \|\boldsymbol{\beta}_l\|_1],$$

where $\|\cdot\|_p$ is the L_p norm for a vector. The penalization on the covariates within each factor is of standard lasso type, hence introduces within-group variable sparsity, while the penalization on the intercept is of exponential type e^{-x} , which is equivalent to penalizing the intercept α_l in the model specified in Eq.(2.1) to the direction towards infinity. Due to the parametrization, the penalization on the group intercept would not penalize any intercept to exactly infinity and hence would not introduce group sparsity directly.

With the lasso-type penalization,

$$\begin{aligned}Q_l(\boldsymbol{\theta}|\boldsymbol{\theta}^{(m)}) &= - \sum_{i=1}^n \left\{ \delta_i \eta_{il}^{(m)} \left[\left(\frac{1}{\sigma_l} - 1 \right) \log T_i - \log \sigma_l - \frac{\mu_{il}}{\sigma_l} \right] - \left(\frac{T_i}{\exp(\mu_{il})} \right)^{1/\sigma_l} \right\} \\ &\quad + \lambda_1 e^{-\alpha_l} + \lambda_2 \|\boldsymbol{\beta}_l\|_1.\end{aligned}$$

Recalling $\mu_{il} = \alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l$, it follows by Eq.(3.3) that, the partial derivatives w.r.t. α_l and

β_{lj} , $j = 1, \dots, p_l$ with penalization are given as

$$\begin{aligned}\frac{\partial Q_l(\boldsymbol{\theta}|\boldsymbol{\theta}^{(m)})}{\partial \alpha_l} &= \frac{1}{\sigma_l} \sum_{i=1}^n \left[\delta_i \eta_{il}^{(m)} - \left(\frac{T_i}{\exp(\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l} \right] - \lambda_1 e^{-\alpha_l}, \\ \frac{\partial Q_l(\boldsymbol{\theta}|\boldsymbol{\theta}^{(m)})}{\partial \beta_{lj}} &= \frac{1}{\sigma_l} \sum_{i=1}^n X_{ilj} \left[\delta_i \eta_{il}^{(m)} - \left(\frac{T_i}{\exp(\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l} \right] + \lambda_2 \text{sign}(\beta_{lj}),\end{aligned}$$

where $\text{sign}(x)$ is the sign function, being 1, -1 and zero for positive, negative and zero x .

Analogously, the partial derivatives w.r.t. σ_l is given as

$$\begin{aligned}\frac{\partial Q_l(\boldsymbol{\theta}|\boldsymbol{\theta}^{(m)})}{\partial \sigma_l} &= -\frac{1}{\sigma_l^2} \sum_{i=1}^n \left[\delta_i \eta_{il}^{(m)} (\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l - \sigma_l - \log T_i) \right. \\ &\quad \left. + (\log T_i - \alpha_l - \mathbf{X}_{il}^\top \boldsymbol{\beta}_l) \left(\frac{T_i}{\exp(\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l} \right].\end{aligned}$$

The updates for α_l and β_{lj} are achieved via gradient descent, and σ_l can be updated using any one-dimensional optimization method.

3.3 Theoretical Results

In this section, we provide the theoretical results of consistency and asymptotic normality of the MLE and the convergence of the EM algorithm.

The following first five assumptions are required for consistency and asymptotic normality, and the last two assumptions are additional for convergence of the EM algorithm:

Assumption 3.1. *A1. The parameter space Θ is compact.*

A2. The distribution that generates \mathbf{X}_i is light-tailed in terms that $\mathbb{E}\{\exp(\mathbf{X}_i)\} < \infty$.

A3. $\mathbb{P}\{g(T_i|X_i; \boldsymbol{\theta}, \delta_i) \neq g(Y_i|X_i; \boldsymbol{\theta}_0, \delta_i)\} > 0, \forall \boldsymbol{\theta} \in \Theta$ with $\boldsymbol{\theta} \neq \boldsymbol{\theta}_0$, where $\boldsymbol{\theta}_0$ is the true parameter, and

$$g(T_i|X_i; \boldsymbol{\theta}, \delta_i) = \sum_{l=1}^L \left(\frac{T_i^{1/\sigma_l - 1}}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right)^{\delta_i} \exp \left(- \sum_{k=1}^L \left(\frac{T_i}{\exp(\alpha_k + X_{ik}^\top \boldsymbol{\beta}_k)} \right)^{1/\sigma_k} \right).$$

A4. $\boldsymbol{\theta}_0$ is in the interior of Θ .

A5. The Fisher information

$$\begin{aligned} I(\boldsymbol{\theta}) &= \mathbb{E} \left\{ \frac{\partial}{\partial \boldsymbol{\theta}} \log g(T_i|X_i; \boldsymbol{\theta}, \delta_i) \frac{\partial}{\partial \boldsymbol{\theta}^\top} \log g(T_i|X_i; \boldsymbol{\theta}, \delta_i) \right\} \\ &= -\mathbb{E} \left\{ \frac{\partial^2}{\partial \theta_j \partial \theta_k} \log g(T_i|X_i; \boldsymbol{\theta}, \delta_i) \right\} \end{aligned}$$

is well-defined and positive definite at $\boldsymbol{\theta}_0$.

A6. $\sigma_l \geq \epsilon > 0$, $\forall l = 1, \dots, L$. The noise variances are bounded away from 0.

A7. The sequence $\{\boldsymbol{\theta}^{(m)}, m \geq 1\}$ in EM algorithm satisfies $\|\boldsymbol{\theta}^{(m+1)} - \boldsymbol{\theta}^{(m)}\| \rightarrow 0$, as $m \rightarrow \infty$.

We then derive the Theorem 3.1 for consistency and asymptotic normality, and the detailed proofs are listed in the Appendix. The convergence of EM is obtained in the Theorem 3.2 by theorems in Wu (1983).

Theorem 3.1. Denote $\boldsymbol{\theta}_0$ as the true parameter and $\widehat{\boldsymbol{\theta}}_n$ as the MLE. Under assumptions A1~A3, as $n \rightarrow \infty$,

$$\widehat{\boldsymbol{\theta}}_n \xrightarrow{p} \boldsymbol{\theta}_0.$$

If assumptions A1~A5 are satisfied, then as $n \rightarrow \infty$,

$$\sqrt{n}(\widehat{\boldsymbol{\theta}}_n - \boldsymbol{\theta}_0) \xrightarrow{d} \mathcal{N}(0, I(\boldsymbol{\theta}_0)^{-1}),$$

where $I(\boldsymbol{\theta}_0)$ is the Fisher information matrix.

Theorem 3.2. Define the observed-data likelihood

$$L_0(\boldsymbol{\theta}) = \sum_{l=1}^L \left(\frac{t_i^{1/\sigma_l - 1}}{\sigma_l \exp((\alpha_l + \mathbf{X}_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right)^{\delta_i} \exp \left(- \sum_{k=1}^L \left(\frac{t_i}{\exp(\alpha_k + \mathbf{X}_{ik}^\top \boldsymbol{\beta}_k)} \right)^{1/\sigma_k} \right).$$

Under assumptions A1 and A6, all the limit points of $\{\boldsymbol{\theta}^{(m)}\}$ of an EM algorithm are stationary points, and $L_0(\boldsymbol{\theta}^{(m)})$ converges monotonically to $L_0^* = L_0(\boldsymbol{\theta}^*)$ for some stationary point $\boldsymbol{\theta}^* \in \Theta$.

With the additional assumption A7, then $\{\boldsymbol{\theta}^{(m)}\}$ converges to some local maxima $\boldsymbol{\theta}^*$ with $L_0(\boldsymbol{\theta}^*) = L_0^*$.

Under assumptions A1 and A6, the compactness regularity condition (Wu, 1983, Assumption 6) is achieved and $L_0(\boldsymbol{\theta}^{(m)})$ is bounded above, then $\{\boldsymbol{\theta}^{(m)}\}$ converges to stationary points by Wu (1983, Theorem 2). Assumption A7 gives the stop rule for the algorithm, and we stop at $\|\boldsymbol{\theta}^{(m+1)} - \boldsymbol{\theta}^{(m)}\| < \varepsilon$ for simulation ($\varepsilon = 10^{-6}$) and real data analysis ($\varepsilon = 10^{-3}$).

3.4 Expected survival time

Similar to the expected survival time in traditional parametric survival models, we compute the expectation under the min-survival structure. The conditional expectations are not the minimum of the expected values across the risks (groups) due to the heteroskedasticity.

The expectation of T is given by

$$\begin{aligned} \mathbb{E}\{T\} &= \int_0^\infty S(t)dt = \int_0^\infty \exp\left(-\sum_{k=1}^L \left(\frac{t}{\exp(\mu_k)}\right)^{1/\sigma_k}\right) dt \quad \text{by Eq.(2.2)} \\ &= \int_0^M \exp\left(-\sum_{k=1}^L \left(\frac{t}{\exp(\mu_k)}\right)^{1/\sigma_k}\right) dt + \int_M^\infty \exp\left(-\sum_{k=1}^L \left(\frac{t}{\exp(\mu_k)}\right)^{1/\sigma_k}\right) dt \end{aligned}$$

The integral is approximated by a finite integral for $0 \leq t \leq M$, where M is a large real number, while the second part $t > M$ is then approximated by

$$\int_M^\infty \exp\left(-\sum_{k=1}^L \left(\frac{t}{\exp(\mu_k)}\right)^{1/\sigma_k}\right) dt \approx \frac{1}{\sum_{k=1}^L \zeta_k(M)} \exp\left(-\sum_{k=1}^L \left(\frac{M}{\exp(\mu_k)}\right)^{1/\sigma_k}\right)$$

using the Mill's ratio by Lemma 6.7.

We also consider the importance sampling method (Tokdar and Kass, 2010) with proposal

distributions of exponential and Weibull distributions, as well as the Gumbel distribution with integration by logarithmic substitution.

4 Simulation

In this section, we present the results of the estimation procedure using simulation data for the Weibull competing survival model derived in Section 3, and compare its prediction accuracy with the Weibull survival model and the Cox proportional hazards model. The simulation includes three examples with parameters listed in Table 1, where the notation “-” indicates a value of 0 and exclusion from model fitting. Example 1 considers non-overlapping independent variables across competing factors with varying variances. Example 2 involves partially overlapping variables with varying variances. Example 3 includes overlapping variables with coefficients set to 0, also with varying variances. The independent variable \mathbf{X}_i is generated independently and identically distributed from $\mathcal{N}(0, \mathbf{I})$ where \mathbf{I} is the identity matrix. The sample sizes are $n = 1000$, $n = 1500$, and $n = 1500$ for Examples 1, 2, and 3, respectively. Random censorship is applied as follows: 0% and 10% for Example 1; approximately 0%, 10%, 20%, and 30% for Example 2; and approximately 10% and 30% for Example 3.

Table 1: True parameter settings of competing Weibull survival model. The notation "-" in β_j s means a value of 0 and is not included in the model fitting.

		σ	α	β_1	β_2	β_3	β_4	β_5	β_6
Example 1	Competing factor 1	1.0	1.6	1.2	-	-	-	-	-
	Competing factor 2	1.0	1.2	-	2.0	-	-	-	-
	Competing factor 3	1.1	2.1	-	-	1.0	-	-	-
Example 2	Competing factor 1	1.0	1.0	-3.0	2.0	-	1.0	-	-
	Competing factor 2	1.0	1.5	2.0	2.0	-	-	-	-
	Competing factor 3	1.1	1.0	-2.0	3.0	2.0	-	-	-
Example 3	Competing factor 1	1.0	1.0	-3.0	2.0	-	-	-	-
	Competing factor 2	1.0	1.5	-	0.0	2.0	2.0	-	-
	Competing factor 3	1.1	1.0	-	-	-	0.0	-2.0	3.0

In the estimation process, for simplicity, the tuning parameters were set as $\lambda_1 = 0.5$, $\lambda_2 = 0.2$ for Example 1, and $\lambda_1 = 2$, $\lambda_2 = 1$ for Examples 2 and 3, based on various attempts with $\lambda_1 \in (0, 10)$ and $\lambda_2 \in (0, 1)$. The estimates remained stable across these attempts within the specified ranges. Alternatively, cross-validation could be employed for parameter selection.

Table 2 presents the exact number of uncensored (d) and censored (c) samples for three examples and provides the estimated values of the mean and standard errors (SE) for σ , α , β . The results indicate a slight reduction in precision with increasing proportions of censorship. Nonetheless, all parameters are accurately estimated with relatively small standard errors, supporting the theoretical findings derived in Section 3. Additionally, in both two censorship scenarios of Example 3, the two zero coefficients in the second and third competing factors are successfully detected.

To evaluate model performance, we conduct the Weibull survival model and the Cox proportional hazards model, incorporating all explanatory variables in each scenario. For example, in Example 3, all six variables are included. The performance of each model is

assessed using two metrics: the concordance index (C-index; C-statistic) and the integrated area under the curve (iAUC). C-index measures the ability of the model to rank the survival times for pairs of observations correctly (Uno et al., 2011). A higher C-index indicates a better alignment between the predicted and actual ranking of survival times, with a value of 0.5 representing random guessing and a value of 1 indicating perfect prediction. The iAUC is a summary measure of model performance, calculated as the area under the time-dependent receiver operating characteristic (ROC) curve across multiple time points (Heagerty and Zheng, 2005; Uno et al., 2007). Time-dependent ROC curves assess the ability of a model to discriminate between event and non-event outcomes at different time points, and a higher iAUC reflects better overall discriminatory power.

Table 3 summarizes the results, highlighting the best performance achieved by the competing Weibull survival model with the highest C-index and highest iAUC across all scenarios. The competing Weibull model demonstrates superior performance, particularly in more complex cases in Examples 2 and 3. Figure 1 shows the time-dependent ROC curves for three examples, each with 10% censoring, evaluated at the median survival time. The competing Weibull model shows consistently superior performance with higher AUCs. Additionally, the competing Weibull model's performance remains stable across different time cut-offs, while both the Cox and Weibull models exhibit relatively poorer performance at the median cut-off when compared to their performance at either high or low time cut-offs.

Table 2: Estimated parameters of the competing Weibull survival model for three examples with varying levels of random censorship (0% to 30%). Here, n represents the total sample size, d denotes the number of uncensored samples, and c indicates the number of censored data.

		$\hat{\sigma}$ (SE)	$\hat{\alpha}$ (SE)	$\hat{\beta}_1$ (SE)	$\hat{\beta}_2$ (SE)	$\hat{\beta}_3$ (SE)	$\hat{\beta}_4$ (SE)	β_5 (SE)	β_6 (SE)
Example 1 ($n = d = 1000$)	CF 1	0.917 (0.051)	1.626 (0.091)	1.170 (0.082)	-	-	-	-	-
	CF 2	0.994 (0.044)	1.219 (0.088)	-	2.028 (0.076)	-	-	-	-
	CF 3	1.078 (0.068)	2.109 (0.138)	-	-	1.078 (0.115)	-	-	-
Example 1 ($d = 900, c = 100$)	CF 1	0.924 (0.057)	1.623 (0.100)	1.101 (0.090)	-	-	-	-	-
	CF 2	0.970 (0.044)	1.163 (0.088)	-	1.965 (0.076)	-	-	-	-
	CF 3	1.120 (0.074)	2.192 (0.158)	-	-	0.917 (0.136)	-	-	-
Example 2 ($n = d = 1500$)	CF 1	0.911 (0.039)	0.955 (0.085)	-2.907 (0.071)	2.001 (0.053)	-	0.934 (0.052)	-	-
	CF 2	1.071 (0.038)	1.400 (0.101)	2.011 (0.082)	2.007 (0.053)	-	-	-	-
	CF 3	1.101 (0.048)	1.043 (0.129)	-2.000 (0.101)	3.098 (0.070)	2.035 (0.088)	-	-	-
Example 2 ($d = 1339, c = 161$)	CF 1	1.025 (0.040)	1.011 (0.101)	-2.977 (0.085)	1.967 (0.062)	-	0.977 (0.061)	-	-
	CF 2	1.010 (0.038)	1.601 (0.115)	2.011 (0.088)	2.037 (0.062)	-	-	-	-
	CF 3	1.006 (0.043)	0.940 (0.117)	-1.977 (0.094)	2.945 (0.064)	1.971 (0.081)	-	-	-
Example 2 ($d = 1211, c = 289$)	CF 1	1.025 (0.041)	0.962 (0.109)	-2.960 (0.064)	1.947 (0.068)	-	0.954 (0.285)	-	-
	CF 2	0.981 (0.039)	1.487 (0.123)	1.952 (0.092)	1.978 (0.070)	-	-	-	-
	CF 3	0.993 (0.044)	0.931 (0.125)	-1.962 (0.095)	2.948 (0.068)	1.964 (0.083)	-	-	-
Example 2 ($d = 1057, c = 443$)	CF 1	1.019 (0.044)	0.918 (0.120)	-2.924 (0.096)	1.942 (0.075)	-	0.963 (0.069)	-	-
	CF 2	0.989 (0.043)	1.567 (0.146)	1.976 (0.103)	2.048 (0.080)	-	-	-	-
	CF 3	0.991 (0.044)	0.890 (0.132)	-1.953 (0.096)	2.917 (0.073)	1.950 (0.086)	-	-	-
Example 3 ($d = 1350, c = 150$)	CF 1	0.996 (0.037)	1.048 (0.087)	-2.999 (0.064)	2.112 (0.061)	-	-	-	-
	CF 2	1.002 (0.046)	1.477 (0.116)	-	0.000 (0.068)	1.920 (0.076)	2.025 (0.082)	-	-
	CF 3	1.131 (0.041)	0.999 (0.098)	-	-	-	0.000 (0.069)	-2.009 (0.067)	2.965 (0.073)
Example 3 ($d = 1054, c = 446$)	CF 1	0.959 (0.038)	0.929 (0.108)	-2.902 (0.075)	2.093 (0.067)	-	-	-	-
	CF 2	1.031 (0.053)	1.425 (0.173)	-	0.000 (0.084)	1.861 (0.104)	2.000 (0.107)	-	-
	CF 3	1.142 (0.045)	1.000 (0.125)	-	-	-	0.000 (0.078)	-1.987 (0.078)	2.963 (0.086)

Table 3: C-index and iAUC comparisons among competing Weibull, Cox, and Weibull models across different examples. The Cox and Weibull models include all the explanatory variables.

	Models	C-index	iAUC		Models	C-index	iAUC
Example 1 ($n = d = 1000$)	Competing-Weibull	0.744	0.837	Example 1 ($d = 900, c = 100$)	Competing-Weibull	0.746	0.836
	Cox PH	0.718	0.807		Cox PH	0.721	0.809
	Weibull	0.718	0.807		Weibull	0.722	0.809
Example 2 ($n = d = 1500$)	Competing-Weibull	0.865	0.950	Example 2 ($d = 1339, c = 161$)	Competing-Weibull	0.875	0.955
	Cox PH	0.806	0.902		Cox PH	0.816	0.907
	Weibull	0.805	0.902		Weibull	0.816	0.907
Example 2 ($d = 1211, c = 289$)	Competing-Weibull	0.879	0.953	Example 2 ($d = 1057, c = 443$)	Competing-Weibull	0.883	0.952
	Cox PH	0.820	0.904		Cox PH	0.826	0.903
	Weibull	0.820	0.904		Weibull	0.826	0.903
Example 3 ($d = 1350, c = 150$)	Competing-Weibull	0.845	0.935	Example 3 ($d = 1054, c = 446$)	Competing-Weibull	0.851	0.928
	Cox PH	0.755	0.851		Cox PH	0.759	0.842
	Weibull	0.754	0.851		Weibull	0.759	0.842




Figure 1: Time-dependent ROCs for competing-Weibull, Cox, and Weibull models at their median survival times. All cases refer to the 10% random censorship for Example 1 (left), Example 2 (middle), and Example 3 (right).

5 Real Data Applications

Alzheimer’s disease is a neurodegenerative disorder usually characterized by prominent amnesic cognitive impairment and short-term memory difficulties and is the most common cause

of dementia (Knopman et al., 2021). Although the amyloid beta hypothesis is the predominant explanation, the exact causes of Alzheimer’s disease remain poorly understood (Burns and Iliffe, 2009). Definitive diagnosis of Alzheimer’s disease is only possible through autopsy, while clinical diagnoses are categorized as ”possible” or ”probable” based on available findings. Ongoing research aims to develop diagnostic algorithms that identify the most informative biomarker combinations and determine their optimal ordering for specific clinical situations (Chételat et al., 2020).

In this section, we apply the competing Weibull model to identify informative combinations and the optimal ordering of potential risk factors associated with the progression from mild cognitive impairment (MCI) to an Alzheimer’s disease diagnosis. MCI represents the earliest symptomatic stage of cognitive impairment, characterized by mild deficits in one or more cognitive domains while functional abilities remain relatively preserved (Petersen, 2004).

Based on the four waves of the ADNI study (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3) (Mueller et al., 2005), we analyze 1,113 participants diagnosed with MCI at baseline, among whom 359 progressed to dementia during follow-up. Considering the data completeness, we evaluate the relative importance and informative combinations of 8 risk factors (Table 5), related to cognitive function assessment and brain structure imaging, in characterizing disease progression from MCI to Alzheimer’s disease.

Table 4: Description of risk factors.

Variables	Type	Description
RAVLT (immediate)	Cognitive & functional	Total number of words recalled across the 5 learning trials of the Rey Auditory Verbal Learning Test (RAVLT).
Gender	Demographic	Participant gender (1 for male, 0 for female).
RAVLT (perc forgetting)	Cognitive & functional	Percentage of words forgotten in the RAVLT.
LDELTOTAL	Neuropsychological	Total number of story units recalled in the Logical Memory Delayed Recall task from the Wechsler Memory Scale-Revised.
TRABSCOR	Neuropsychological	Time (in seconds) taken to complete Part B of the Trail Making Test
Entorhinal	Neuropathological	Total volume of the bilateral entorhinal cortex, measured in cubic millimetres.
Fusiform	Brain structure	Total volume of the bilateral fusiform gyrus, measured in cubic millimetres.
ICV	Brain structure	Intracranial volume (ICV) derived using UCSF’s (University of California, San Francisco) methodology, measured from T1-weighted MRI scans.
Hippocampus	Brain structure	Total volume of the bilateral hippocampus, measured in cubic millimetres.

With a number of trials, an optimal choice is selected with tuning parameters determined as $\lambda_1 = 0.3$, $\lambda_2 = 0.1$ and four competing groups: (1) RAVLT (immediate), LDELTOTAL, Entorhinal, Fusiform; (2) RAVLT (immediate), Gender, Entorhinal, Fusiform, ICV; (3) RAVLT (perc forgetting), TRABSCOR, Entorhinal, ICV; (4) Hippocampus. This configu-

ration achieves the best performance with a C-index of 0.811 and an iAUC of 0.857. For comparison, the simple Weibull model and Cox PH model yield C-indices of 0.806 and 0.807, respectively, and iAUC values of 0.855 and 0.856. While the iAUCs are similar across models, our competing Weibull model provides better performance in estimating short survival times for severe cases. This is further illustrated by time-dependent ROC curves at the 10th percentile survival time ($t = 357$) and at 2 years ($t = 730$) in Figure 2 (left and middle).




Figure 2: Time-dependent ROCs (left, middle) for competing-Weibull, Cox, and Weibull models at 10 percentile survival time ($t = 357$) and at 2 years ($t = 730$). Estimated time-varying winning probability (right) of four competing groups for uncensored samples.

Table 5 presents the estimated scale parameters and regression coefficients with standard errors for all risk factors. The estimates and statistical significance across the four competing groups remain consistent with those obtained from the simple Weibull model (for survival time) and the Cox PH model (for hazards). The model effectively identifies the weak effect of gender using the tuning parameter ($\lambda_2 = 0.1$) for within-group sparsity, where its non-significance is also confirmed in the other models.

Table 5: Result of models with estimates of mean (SE). The notation “-” means variables excluded from the competing group.

Model	Intercept	RAVLT (immediate)	Gender	RAVLT (perc forgetting)	LDELTOTAL	TRABSCOR	Hippocampus	Entorhinal	Fusiform	ICV	Scale ($\hat{\sigma}$)	
Competing-	CF 1	15.168 (0.804)	2.429 (0.327)	-	-	3.634 (0.485)	-	-	0.832 (0.243)	0.220 (0.237)	-	1.862 (0.177)
	CF 2	16.212 (1.254)	2.928 (0.446)	0.000 (1.074)	-	-	-	0.164 (0.355)	2.932 (0.516)	-2.840 (0.388)	-	1.843 (0.196)
Weibull	CF 3	18.745 (1.458)	-	-	-1.945 (0.561)	-	-3.233 (0.494)	-	-0.519 (0.358)	-	-2.064 (0.366)	2.091 (0.240)
	CF 4	8.232 (0.064)	-	-	-	-	0.863 (0.052)	-	-	-	-	0.834 (0.041)
Weibull (time)	8.074 (0.094)	0.399 (0.076)	0.235 (0.121)	-0.197 (0.064)	0.255 (0.062)	-0.132 (0.045)	0.254 (0.070)	0.100 (0.064)	0.175 (0.064)	-0.165 (0.062)	0.761 (0.033)	
Cox PH (risk)	-	-0.522 (0.099)	-0.280 (0.161)	0.235 (0.084)	-0.351 (0.079)	0.150 (0.060)	-0.279 (0.093)	-0.132 (0.085)	-0.226 (0.084)	0.231 (0.080)	-	

Table 6 and Figure 2 (right) illustrate the relative importance of competing factors at the time of Alzheimer’s diagnosis and overtime for the uncensored sample. At the event time

(Alzheimer’s diagnosis), the Hippocampus emerges as the most influential factor (86.2%), followed by the competing factor 1 (RAVLT (immediate), LDETOTAL, Entorhinal, Fusiform) at 8%. The time-varying relative importance is estimated based on the parameters of the optimal model, indicating that all factors contribute critically to short-term prediction, whereas the Hippocampus becomes dominant for longer-term analysis (beyond one year).

Table 6: Average winning probability (relative importance) of competing factors for uncensored sample.

Competing Factors	Winning probability at the event time
RAVLT (immediate), LDETOTAL, Entorhinal, Fusiform	0.083
RAVLT (immediate), Gender, Entorhinal, Fusiform, ICV	0.024
RAVLT (perc forgetting), TRABSCOR, Entorhinal, ICV	0.031
Hippocampus	0.862

From an accuracy perspective, our approach achieves improved predictive performance by optimizing the combination of the same 8 risk factors, leading to a more precise characterization of disease progression. From a cost-effectiveness perspective, the time-varying relative importance analysis suggests that the essential measurements can be reduced to factors in groups 1 and 4 (RAVLT (immediate), LDETOTAL, Entorhinal, Fusiform, and Hippocampus) for short-term survival prediction, and group 4 (Hippocampus) for long-term prediction.

6 Discussions and Conclusion

In this paper, we proposed a competing Weibull survival model for multiple causes, as a natural extension of the Weibull accelerated failure time model to the max-linear family. This model keeps the linear structure within each competing group, maintaining the interpretability of the Weibull model, and employs the minimum structure to allow non-Weibull survival time and competition across the factors. Our proposal also enables incorporation of

lasso or other types of penalization for within and between group sparsity, facilitates effective exploration of aetiology and biomarker combinations for neurodegenerative disease, as well as the measure of the disease burden of comorbidity mortality.

By augmenting the latent variable of the dominant factor, our approach enables the simultaneous estimation of regression coefficients and winning probabilities (weights of contributing causes) via the EM algorithm, while maintaining consistency and asymptotic normality under regularity conditions. This data-driven weight estimation method dynamically adapts to individual characteristics and temporal variations, providing a more realistic representation of real-life cases compared to methods that rely on predetermined, population-based weights (Breger et al., 2020; Dobson et al., 2023). The estimated weights also help assess cause designation and identify misclassification errors, especially when assigning an underlying cause of death, which often involves subjective judgment and significant error rates (Johansson and Westerling, 2000). Moreover, in biomarker exploration, prior knowledge of specific causes or predefined weights is often unavailable or inappropriate. Our framework is then useful for identifying the optimal combination and ordering of biomarkers, whether by improving predictive accuracy based on measured biomarkers, reducing examination costs while maintaining acceptable accuracy, or exploring potential biomarkers from large-scale data (such as genetic information) through penalization techniques.

Our competing structure follows the latent survival time approach, but the multiple-cause setting differs from traditional competing risks and causes attribution analysis. As discussed in Moreno-Betancur et al. (2017), the multiple-cause setting does not resolve the traditional competing risks problem in a causal sense. Each individual’s observed time-to-event corresponds to a single combination of causes, while times-to-event for alternative combinations remain unobservable. Likewise, in the complete likelihood, the failure rate component $f(t, K = l)$ depends on both the “marginal” failure rate for the l -th cause and the survival probability of other causes. Therefore, the independence of potential times-to-event remains unidentifiable, as does the counterfactual “marginal” survival time without other competing causes (Prentice et al., 1978), limiting valid inference to observed cause combinations. This

setting aligns more closely with the cause-mixed cause-specific hazard model, which is better suited for studying disease aetiology, rather than estimating a patient’s clinical prognosis or guiding resource allocation through subdistributional models, as discussed in [Austin et al. \(2016\)](#); [Lau et al. \(2009\)](#).

Strategy and criteria for variable selection are crucial, particularly in biomarker discovery. In our application to Alzheimer’s disease, the complexity lies in determining both the number of competing groups and the allocation of eight biomarkers. Rather than conducting a global search, we employ a man-machine strategy to select a model that performs well in the c-index and iAUC, based on a predetermined four-group structure. Identifying the global optimal option can be more complex, especially in genomic studies ([Zhang, 2021, 2022a,b](#)). We recommend incorporating evaluation criteria that effectively balance parsimony and goodness of fit, considering factors such as the number of variables, number of groups, overall accuracy, redundancy, and similar effects of variables, as proposed by ([Liu et al., 2024](#)) for logistic max-linear models. Additionally, an automatic selection algorithm is encouraged to explore possible configurations, further enhancing efficiency and comprehensiveness. A similar approach has been applied to local maxima searching in [LeBlanc et al. \(2006\)](#), though their algorithm was developed within a simpler modelling framework.

Both theoretical and applied extensions of the max-linear family present promising directions for future research. Our approach captures dependence among causes through shared predictors (e.g., common shocks, common genes) across competing groups. Theoretically, modelling dependence between multiple causes (e.g., diseases) via error terms could be explored using copula-based approaches (e.g., Archimedean copulas), as in multivariate time modelling ([Bandein-Roche and Liang, 2002](#); [Lo and Wilke, 2010](#)), though this may affect asymptotic properties. Incorporating time-varying covariates using the concept of martingales may help retain desirable asymptotic properties. A semi-parametric framework integrating cause-specific hazards with multiple-cause models, implemented via the EM algorithm, could enhance estimation flexibility and accuracy. It requires advanced tools such as non-parametric maximum likelihood estimation (NPMLE), profile likelihood methods,

and other techniques discussed in (Mao and Lin, 2017). On the applied side, key challenges include developing interpretable methods for group-wise and within-group variable selection, along with the expertise needed for meaningful explanation. Applications beyond health research with competing risks, such as enterprise bankruptcy risk assessment and financial distress analysis (Gepp and Kumar, 2015) could also be explored.

Appendix

In this section, we will prove Theorem 3.1 for the consistency of the MLE for the parameters involved (Lemma 6.4 which required Lemmas 6.1~6.3) and its asymptotic normality based further on Lemmas 6.5 and 6.6.

Lemma 6.1. *Let $\boldsymbol{\theta}_l = (\sigma_l, \alpha_l, \boldsymbol{\beta}_l^\top)^\top$, $\boldsymbol{\theta} = (\boldsymbol{\theta}_1^\top, \dots, \boldsymbol{\theta}_L^\top)^\top$, and $X_i = (X_{i1}, \dots, X_{iL})$, $\widehat{Q}_n(\boldsymbol{\theta}) = \frac{1}{n} \ell(\boldsymbol{\theta}) = \frac{1}{n} \sum_{i=1}^n \log g(T_i|X_i; \boldsymbol{\theta}, \delta_i)$ and $Q(\boldsymbol{\theta}) = \mathbb{E}_{\boldsymbol{\theta}_0} \{\log g(T_i|X_i; \boldsymbol{\theta}, \delta_i)\}$, where*

$$\begin{aligned} \ell(\boldsymbol{\theta}) &= \sum_{i=1}^n \log g(T_i|X_i; \boldsymbol{\theta}, \delta_i) = \log [f(T_i; \boldsymbol{\theta}, X_i)^{\delta_i} S(T_i; \boldsymbol{\theta}, X_i)^{1-\delta_i}] \\ &= \sum_{i=1}^n \delta_i \log \left(\sum_{1 \leq l \leq L} \frac{T_i^{1/\sigma_l - 1}}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right) - \sum_{1 \leq l \leq L} \left(\frac{T_i}{\exp(\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l}. \end{aligned}$$

Suppose assumptions A1 and A2 hold, then

$$\sup_{\boldsymbol{\theta} \in \Theta} |\widehat{Q}_n(\boldsymbol{\theta}) - Q(\boldsymbol{\theta})| \xrightarrow{p} 0.$$

Lemma 6.2 (Jennrich (1969, Theorem 2)). *Let g be a function on $\mathcal{X} \times \Theta$ where \mathcal{X} is a Euclidean space and Θ is a compact subset of a Euclidean space. Let $g(x, \theta)$ be a continuous function of θ for each x and a measurable function of x for each θ . Assume also that $|g(x, \theta)| \leq h(x)$ for all x and θ , where h is integrable with respect to a distribution function F on \mathcal{X} . If x_1, x_2, \dots is a random sample from F then for almost every sequence (x_i) ,*

$$n^{-1} \sum_{i=1}^n g(x_i, \theta) \rightarrow \int g(x, \theta) dF(x)$$

uniformly for all $\theta \in \Theta$.

Proof of Lemma 6.1. To apply Lemma 6.2 with assumptions A1 and A2, we only need to find an upper bound function $h(T_i, X_i)$, such that $|\log g(T_i|X_i; \boldsymbol{\theta}, \delta_i)| \leq h(T_i, X_i)$, and $\mathbb{E}\{h(T_i, X_i)\} < \infty$ for both T_i and X_i .

Firstly, we show that $\log g(T_i|X_i; \boldsymbol{\theta}, \delta_i)$ is bounded from above by $h(T_i, X_i)$,

$$\begin{aligned}
\log g(T_i|X_i; \boldsymbol{\theta}, \delta_i) &= \log [f(T_i; \boldsymbol{\theta}, X_i)^{\delta_i} S(T_i; \boldsymbol{\theta}, X_i)^{1-\delta_i}] \\
&\leq \delta_i \log f(T_i; \boldsymbol{\theta}, X_i) \\
&= \delta_i \log \left(\sum_{l=1}^L \frac{T_i^{1/\sigma_l-1}}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \exp \left(- \sum_{k=1}^L \left(\frac{T_i}{\exp(\alpha_k + X_{ik}^\top \boldsymbol{\beta}_k)} \right)^{1/\sigma_k} \right) \right) \\
&\leq \delta_i \log \left(\sum_{l=1}^L \frac{T_i^{1/\sigma_l-1}}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \exp \left(- \left(\frac{T_i}{\exp(\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l} \right) \right) \\
&=: \delta_i \log \left(\sum_{l=1}^L \psi(T_i; \sigma_l, \alpha_l, X_{il}, \boldsymbol{\beta}_l) \right).
\end{aligned}$$

Note that $\psi(t; \sigma_l, \alpha_l, X_{il}, \boldsymbol{\beta}_l)$, $t > 0$, is the Weibull density with scale parameter $\exp(\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)$ and shape parameter $1/\sigma_l$. Thus for $0 < t < 1$, we have $t^{-1} > t^{1/\sigma_l-1}$, and

$$\begin{aligned}
\delta_i \log \left(\sum_{l=1}^L \psi(t; \sigma_l, \alpha_l, X_{il}, \boldsymbol{\beta}_l) \right) &\leq \delta_i \log \left(\sum_{1 \leq l \leq L} \frac{t^{1/\sigma_l-1}}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right) \\
&\leq \left| \log \left(\sum_{1 \leq l \leq L} \frac{t^{-1}}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right) \right| \\
&\leq |\log t| + \left| \log \left(\sum_{1 \leq l \leq L} \frac{1}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right) \right| \\
&=: h_1(t, X_i).
\end{aligned}$$

As for $t \geq 1$, when $\sigma_l \geq 1$, the Weibull density is monotonically decreasing, and

$$\frac{t^{1/\sigma_l-1}}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \leq \frac{1}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)}, \quad t \geq 1,$$

when $0 < \sigma_l < 1$, the Weibull density reaches the max at the mode $t_0 = \exp(\alpha_l + X_{il}^\top \boldsymbol{\beta}_l) (1 -$

$\sigma_l)^{\sigma_l}$, with the value

$$\psi(t_0; \sigma_l, \alpha_l, X_{il}, \boldsymbol{\beta}_l) = \frac{(1 - \sigma_l)^{1 - \sigma_l}}{\sigma_l \exp(\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)} \exp(-(1 - \sigma_l)).$$

Combine the two cases for $t > 1$, we have

$$\begin{aligned} & \delta_i \log \left(\sum_{l=1}^L \psi(t; \sigma_l, \alpha_l, X_{il}, \boldsymbol{\beta}_l) \right) \\ & \leq \delta_i \log \left(\sum_{1 \leq l \leq L} \left[\frac{1}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} + \frac{(1 - \sigma_l)^{1 - \sigma_l}}{\sigma_l \exp(\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)} \exp(-(1 - \sigma_l)) \right] \right) \\ & \leq \left| \log \left(\sum_{1 \leq l \leq L} \left[\frac{1}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} + \frac{(1 - \sigma_l)^{1 - \sigma_l}}{\sigma_l \exp(\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)} \exp(-(1 - \sigma_l)) \right] \right) \right| \\ & =: h_2(t, X_i). \end{aligned}$$

Then the upper bound $h(T_i, X_i) = h_1(T_i, X_i) + h_2(T_i, X_i)$. Under assumption *A1* for the compact Θ and given X_{il} , both $h_2(T_i, X_i)$ and the second term of $h_1(T_i, X_i)$ are constant. For the first term in $h_1(T_i, X_i)$, which is $|\log T_i|$, we have

$$\begin{aligned} \mathbb{E} \{ |\log T_i| \} & = \int_0^\infty |\log t| g(t|X_i; \boldsymbol{\theta}, \delta_i) dt \\ & = \int_0^\infty |\log t| \sum_{l=1}^L \left(\frac{t^{1/\sigma_l - 1}}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right)^{\delta_i} \exp \left(- \sum_{k=1}^L \left(\frac{t}{\exp(\alpha_k + X_{ik}^\top \boldsymbol{\beta}_k)} \right)^{1/\sigma_k} \right) dt \\ & \leq \int_0^\infty \sum_{l=1}^L |\log t| \left(\frac{t^{1/\sigma_l - 1}}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right)^{\delta_i} \exp \left(- \left(\frac{t}{\exp(\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l} \right) dt \\ & = \sum_{l=1}^L \int_0^\infty |\log t| \left(\frac{t^{1/\sigma_l - 1}}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right)^{\delta_i} \exp \left(- \left(\frac{t}{\exp(\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l} \right) dt \\ & = \delta_i \sum_{l=1}^L \int_0^\infty |\log t| \psi(t; \sigma_l, \alpha_l, X_{il}, \boldsymbol{\beta}_l) dt \\ & \quad + (1 - \delta_i) \sum_{l=1}^L \int_0^\infty |\log t| \exp \left(- \left(\frac{t}{\exp(\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l} \right) dt, \end{aligned}$$

where both integrals are finite (the first one is finite according to the properties of Weibull distribution). Hence, $\mathbb{E}_T \{ h(T_i, X_i) \} < \infty$ and under assumption *A2* we have $\mathbb{E}_X \{ h(T_i, X_i) \} <$

∞ , which indicates that $h(T_i, X_i)$ is a proper upper-bounded function.

Now we show the lower bound. By Jensen's inequality and concavity of logarithm function, we have

$$\begin{aligned}
& \log\left(\frac{1}{L}\right) + \log g(T_i|X_i; \boldsymbol{\theta}, \delta_i) \\
&= \log \left[\frac{1}{L} \sum_{l=1}^L \left(\frac{T_i^{1/\sigma_l-1}}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right)^{\delta_i} \exp \left(- \sum_{k=1}^L \left(\frac{T_i}{\exp(\alpha_k + X_{ik}^\top \boldsymbol{\beta}_k)} \right)^{1/\sigma_k} \right) \right] \\
&\geq \frac{1}{L} \sum_{l=1}^L \log \left[\left(\frac{T_i^{1/\sigma_l-1}}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right)^{\delta_i} \exp \left(- \sum_{k=1}^L \left(\frac{T_i}{\exp(\alpha_k + X_{ik}^\top \boldsymbol{\beta}_k)} \right)^{1/\sigma_k} \right) \right] \\
&=: \frac{1}{L} \sum_{l=1}^L g_l(T_i|X_i; \boldsymbol{\theta}_l, \delta_i).
\end{aligned}$$

Clearly, we have

$$\begin{aligned}
|g_l(T_i|X_i; \boldsymbol{\theta}_l, \delta_i)| &= \left| \delta_i \log \left(\frac{T_i^{1/\sigma_l-1}}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right) - \sum_{k=1}^L \left(\frac{T_i}{\exp(\alpha_k + X_{ik}^\top \boldsymbol{\beta}_k)} \right)^{1/\sigma_k} \right| \\
&\leq |(1/\sigma_l - 1) \log T_i| + |\log \sigma_l| + \left| \frac{\alpha_l + X_{il}^\top \boldsymbol{\beta}_l}{\sigma_l} \right| + \sum_{k=1}^L \left(\frac{T_i}{\exp(\alpha_k + X_{ik}^\top \boldsymbol{\beta}_k)} \right)^{1/\sigma_k} \\
&=: G(T_i, X_i).
\end{aligned}$$

Next, we show that $\mathbb{E}\{G(T_i, X_i)\} \leq \infty$ for both T_i and X_i . Under assumptions A1 and A2, $\mathbb{E}\{G(T_i, X_i)\} \leq \infty$ for both T_i and X_i , where $\mathbb{E}\{|\log T_i|\} < \infty$ by previous calculations, and $\mathbb{E}\{T_i^{1/\sigma_k}\} < \infty$ by

$$\begin{aligned}
\mathbb{E}\{T_i^{1/\sigma_k}\} &\leq \delta_i \sum_{l=1}^L \int_0^\infty t^{1/\sigma_k} \psi(t; \sigma_l, \alpha_l, X_{il}, \boldsymbol{\beta}_l) dt \\
&\quad + (1 - \delta_i) \sum_{l=1}^L \int_0^\infty t^{1/\sigma_k} \exp \left(- \left(\frac{t}{\exp(\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l} \right) dt,
\end{aligned}$$

where both integrals are finite, by the properties of Weibull distribution.

Therefore, all the conditions in Lemma 6.2 have been verified, hence Lemma 6.1 is proved. \square

Lemma 6.3. *Suppose that assumptions A1 and A3 hold, there exists $\boldsymbol{\theta}_0 \in \Theta$ such that $\forall \epsilon > 0$,*

$$\sup_{\boldsymbol{\theta} \notin B(\boldsymbol{\theta}_0, \epsilon)} Q(\boldsymbol{\theta}) < Q(\boldsymbol{\theta}_0).$$

Proof. It follows by Jensen's inequality that

$$\begin{aligned} Q(\boldsymbol{\theta}) - Q(\boldsymbol{\theta}_0) &= \mathbb{E}_{\boldsymbol{\theta}_0} \left\{ \log \frac{g(T_i|X_i; \boldsymbol{\theta}, \delta_i)}{g(T_i|X_i; \boldsymbol{\theta}_0, \delta_i)} \right\} \\ &\leq \log \mathbb{E}_{\boldsymbol{\theta}_0} \{g(T_i|X_i; \boldsymbol{\theta}, \delta_i)/g(T_i|X_i; \boldsymbol{\theta}_0, \delta_i)\} = 0. \end{aligned}$$

Under assumption A3, the inequality is strict, and $\boldsymbol{\theta}_0$ is the unique maximizer of $Q(\boldsymbol{\theta})$ over Θ . Noting that Θ is compact (assumption A1) and $Q(\boldsymbol{\theta})$ is continuous, Lemma 6.3 follows. \square

Lemma 6.4 (Extremum Consistency Theorem, [Newey and McFadden \(1994, Theorem 2.1\)](#)).

If there is a function $Q(\boldsymbol{\theta})$, such that

1. $Q(\boldsymbol{\theta})$ is uniquely maximized at $\boldsymbol{\theta}_0$,
2. Θ is compact,
3. $Q(\boldsymbol{\theta})$ is continuous,
4. $\widehat{Q}_n(\boldsymbol{\theta})$ converges uniformly in probability to $Q(\boldsymbol{\theta})$,

then

$$\widehat{\boldsymbol{\theta}}_n \xrightarrow{p} \boldsymbol{\theta}_0.$$

For asymptotic normality, we first need to show

$$\mathbb{E} \left\{ \left| \frac{\partial}{\partial \boldsymbol{\theta}} \log g(T_i|X_i; \boldsymbol{\theta}, \delta_i) \right| \right\} < \infty \tag{6.1}$$

and

$$\mathbb{E} \left\{ \left| \frac{\partial^2}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^\top} \log g(T_i|X_i; \boldsymbol{\theta}, \delta_i) \right| \right\} < \infty. \tag{6.2}$$

To show Eq.(6.1), we rewrite $\log g$ (recall Lemma 6.1) as

$$\begin{aligned}\log g(T_i|X_i; \boldsymbol{\theta}, \delta_i) &= \delta_i \log \sum_{l=1}^L \left(\frac{T_i^{1/\sigma_l - 1}}{\sigma_l \exp((\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)/\sigma_l)} \right) - \sum_{k=1}^L \left(\frac{T_i}{\exp(\alpha_k + X_{ik}^\top \boldsymbol{\beta}_k)} \right)^{1/\sigma_k} \\ &= \delta_i \log \sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right) - \sum_{k=1}^L S_{ik}^{1/\sigma_k},\end{aligned}$$

where $S_{il} = T_i / \exp(\alpha_l + X_{il}^\top \boldsymbol{\beta}_l) > 0$, and $\mathbb{E}\{|S_{il}|\} < \infty$, $\mathbb{E}\{|\log S_{il}|\} < \infty$ by previous calculations under assumptions *A1* and *A2*. In the following, we consider only the case with non-censoring case (that is all δ_i 's equal 1).

First, we have

$$\begin{aligned}\left| \frac{\partial \log g(T_i|X_i; \boldsymbol{\theta}, 1)}{\partial \sigma_l} \right| &= \left| \frac{\left(-\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right)}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} + \frac{S_{il}^{1/\sigma_l} \log S_{il}}{\sigma_l^2} \right| \\ &\leq \frac{\left| \frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right|}{\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l}} + \left| \frac{S_{il}^{1/\sigma_l} \log S_{il}}{\sigma_l^2} \right| \\ &\leq \left| \frac{\log S_{il} + \sigma_l}{\sigma_l^2} \right| + \frac{S_{il}^{1/\sigma_l}}{\sigma_l^2} |\log S_{il}|.\end{aligned}\tag{6.3}$$

Now, we consider the partial derivative w.r.t. α_l .

$$\begin{aligned}\left| \frac{\partial \log g(T_i|X_i; \boldsymbol{\theta}, 1)}{\partial \alpha_l} \right| &= \left| \frac{\partial \log g(T_i|X_i; \boldsymbol{\theta}, 1)}{\partial S_{il}} \cdot \frac{\partial S_{il}}{\partial \alpha_l} \right| \\ &= \left| \frac{-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l}}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} + \frac{S_{il}^{1/\sigma_l}}{\sigma_l} \right| \leq \left| \frac{\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l}}{\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l}} \right| + \left| \frac{S_{il}^{1/\sigma_l}}{\sigma_l} \right| \leq \frac{1 + S_{il}^{1/\sigma_l}}{\sigma_l}.\end{aligned}\tag{6.4}$$

Similarly,

$$\left| \frac{\partial \log g(T_i|X_i; \boldsymbol{\theta}, 1)}{\partial \beta_l} \right| = \left| \frac{\partial \log g(T_i|X_i; \boldsymbol{\theta}, 1)}{\partial \alpha_l} \cdot X_{il} \right| \leq |X_{il}| \frac{1 + S_{il}^{1/\sigma_l}}{\sigma_l}.\tag{6.5}$$

Again, under assumptions *A1* and *A2*, all first-order derivatives are bounded by integrable

functions.

Next, we show Eq.(6.2). We have second-order derivative w.r.t. σ_l and σ_k . Recalling Eq.(6.3), we have for $l \neq k$

$$\begin{aligned}
\left| \frac{\partial^2 \log g(T_i|X_i; \boldsymbol{\theta}, 1)}{\partial \sigma_l \partial \sigma_k} \right| &= \left| \frac{\partial}{\partial \sigma_k} \left[\frac{\left(-\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right) + \frac{S_{il}^{1/\sigma_l} \log S_{il}}{\sigma_l^2}}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} \right] \right| \\
&= \left| \frac{\left(-\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right) \left(-\frac{S_{ik}^{1/\sigma_k} (\log S_{ik} + \sigma_k)}{T_i \sigma_l^3} \right)}{\left(\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right) \right)^2} \right| \\
&\leq \left| \frac{\left(-\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right) \left(-\frac{S_{ik}^{1/\sigma_k} (\log S_{ik} + \sigma_k)}{T_i \sigma_l^3} \right)}{\left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right) \left(\frac{1}{T_i \sigma_k} S_{ik}^{1/\sigma_k} \right)} \right| \\
&\leq \left| \frac{\log S_{il} + \sigma_l}{\sigma_l^2} \right| \cdot \left| \frac{\log S_{ik} + \sigma_k}{\sigma_k^2} \right|
\end{aligned}$$

and for $l = k$,

$$\left| \frac{\partial^2 \log g(T_i|X_i; \boldsymbol{\theta}, 1)}{\partial \sigma_l^2} \right| = \left| \frac{\partial}{\partial \sigma_l} \left[\frac{\left(-\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right) + \frac{S_{il}^{1/\sigma_l} \log S_{il}}{\sigma_l^2}}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} \right] \right|$$

with

$$\left| \frac{\partial}{\partial \sigma_l} \frac{S_{il}^{1/\sigma_l} \log S_{il}}{\sigma_l^2} \right| = \left| -\frac{S_{il}^{1/\sigma_l} ((\log S_{il})^2 + 2\sigma_l \log S_{il})}{\sigma_l^4} \right| \leq \left| \frac{S_{il}^{1/\sigma_l} (\log S_{il})^2}{\sigma_l^4} \right| + \left| \frac{2S_{il}^{1/\sigma_l} \log S_{il}}{\sigma_l^3} \right|$$

and

$$\begin{aligned}
\left| \frac{\partial}{\partial \sigma_l} \frac{\left(-\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right)}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} \right| &= \left| \frac{1}{T_i} \frac{-\frac{S_{il}^{1/\sigma_l} (\log S_{il})^2}{\sigma_l^5} - \frac{4S_{il}^{1/\sigma_l} \log S_{il}}{\sigma_l^4} - \frac{2S_{il}^{1/\sigma_l}}{\sigma_l^3}}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} - \frac{\left(-\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right)^2}{\left(\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right) \right)^2} \right| \\
&\leq \frac{(\log S_{il})^2}{\sigma_l^4} + \left| \frac{4 \log S_{il}}{\sigma_l^3} \right| + \left| \frac{2}{\sigma_l^2} \right| + \left(\frac{\log S_{il} + \sigma_l}{\sigma_l^2} \right)^2.
\end{aligned}$$

Next, we deal with the second-order derivative w.r.t. α_l and α_k . Recalling Eq.(6.4), we have for $l \neq k$

$$\begin{aligned} \left| \frac{\partial^2 \log g(T_i|X_i; \boldsymbol{\theta}, 1)}{\partial \alpha_l \partial \alpha_k} \right| &= \left| \frac{\partial}{\partial \alpha_k} \frac{\left(-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l}\right)}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l}\right)} + \frac{\partial}{\partial \alpha_k} \frac{S_{il}^{1/\sigma_l}}{\sigma_l} \right| \\ &= \frac{\left(-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l}\right) \left(-\frac{1}{T_i \sigma_k^2} S_{ik}^{1/\sigma_k}\right)}{\left(\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l}\right)\right)^2} \leq \frac{1}{\sigma_l \sigma_k} \end{aligned}$$

and for $l = k$

$$\left| \frac{\partial^2 \log g(T_i|X_i; \boldsymbol{\theta}, 1)}{\partial \alpha_l^2} \right| \leq \left| \frac{\partial}{\partial \alpha_l} \frac{-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l}}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l}\right)} \right| + \left| \frac{\partial}{\partial \alpha_l} \frac{S_{il}^{1/\sigma_l}}{\sigma_l} \right| =: I + II,$$

where $II = S_{il}^{1/\sigma_l} / \sigma_l^2$ and

$$\begin{aligned} I &= \left| \frac{\frac{1}{T_i \sigma_l^3} S_{il}^{1/\sigma_l}}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l}\right)} - \frac{\left(-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l}\right)^2}{\left(\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l}\right)\right)^2} \right| \\ &\leq \left| \frac{\frac{1}{T_i \sigma_l^3} S_{il}^{1/\sigma_l}}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l}\right)} \right| + \left| \frac{\left(-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l}\right)^2}{\left(\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l}\right)\right)^2} \right| \leq \frac{2}{\sigma_l^2}. \end{aligned}$$

Further, we deal with the second-order derivative w.r.t. β_l and β_k . Recalling Eqs.(6.4) and

(6.5), we have for $l \neq k$

$$\begin{aligned} \left| \frac{\partial^2 \log g(T_i | X_i; \boldsymbol{\theta}, 1)}{\partial \beta_l \partial \beta_k} \right| &\leq \left| \frac{\partial}{\partial \beta_k} \frac{\left(-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l} X_{il} \right)}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} \right| + \left| \frac{\partial}{\partial \beta_k} \frac{S_{il}^{1/\sigma_l} X_{il}}{\sigma_l} \right| \\ &= \left| \frac{\left(-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l} X_{il} \right) \left(-\frac{1}{T_i \sigma_k^2} S_{ik}^{1/\sigma_k} X_{ik} \right)}{\left(\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right) \right)^2} \right| \leq \frac{|X_{il} X_{ik}|}{\sigma_l \sigma_k} \end{aligned}$$

and for $l = k$

$$\begin{aligned} \left| \frac{\partial^2 \log g(T_i | X_i; \boldsymbol{\theta}, 1)}{\partial \beta_l^2} \right| &= \left| \frac{\frac{1}{T_i \sigma_l^3} S_{il}^{1/\sigma_l} X_{il}^2}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} - \frac{\left(-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l} X_{il} \right)^2}{\left(\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right) \right)^2} - \frac{S_{il}^{1/\sigma_l} X_{il}^2}{\sigma_l^2} \right| \\ &\leq \left| \frac{\frac{1}{T_i \sigma_l^3} S_{il}^{1/\sigma_l} X_{il}^2}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} \right| + \left| \frac{\left(-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l} X_{il} \right)^2}{\left(\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right) \right)^2} \right| + \left| \frac{S_{il}^{1/\sigma_l} X_{il}^2}{\sigma_l^2} \right| \\ &\leq \frac{2X_{il}^2}{\sigma_l^2} + \frac{S_{il}^{1/\sigma_l} X_{il}^2}{\sigma_l^2}. \end{aligned}$$

Lastly, for other second-order derivatives w.r.t. (σ_l, α_k) and (σ_l, β_k) , we recall Eq.(6.3) for $l \neq k$

$$\begin{aligned} \left| \frac{\partial^2 \log g(T_i | X_i; \boldsymbol{\theta}, 1)}{\partial \sigma_l \partial \alpha_k} \right| &= \left| \frac{\partial}{\partial \alpha_k} \frac{\left(-\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right)}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} + \frac{\partial}{\partial \alpha_k} \frac{S_{il}^{1/\sigma_l} \log S_{il}}{\sigma_l^2} \right| \\ &= \left| \frac{\left(-\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right) \left(-\frac{1}{T_i \sigma_k^2} S_{ik}^{1/\sigma_k} \right)}{\left(\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right) \right)^2} \right| \leq \frac{1}{\sigma_k} \left| \frac{\log S_{il} + \sigma_l}{\sigma_l^2} \right| \end{aligned}$$

and

$$\left| \frac{\partial^2 \log g(T_i | X_i; \boldsymbol{\theta}, 1)}{\partial \sigma_l \partial \beta_k} \right| \leq \frac{|X_{ik}|}{\sigma_k} \left| \frac{\log S_{il} + \sigma_l}{\sigma_l^2} \right|.$$

Now, for $l = k$

$$\left| \frac{\partial^2 \log g(T_i | X_i; \boldsymbol{\theta}, 1)}{\partial \sigma_l \partial \alpha_l} \right| = \left| \frac{\partial}{\partial \alpha_l} \frac{\left(-\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right)}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} + \frac{\partial}{\partial \alpha_l} \frac{S_{il}^{1/\sigma_l} \log S_{il}}{\sigma_l^2} \right| =: |I + II|$$

with

$$\begin{aligned} II &= -\frac{S_{il}^{1/\sigma_l} \log S_{il}}{\sigma_l^3} - \frac{S_{il}^{1/\sigma_l}}{\sigma_l^2} \leq \frac{S_{il}^{1/\sigma_l} |\log S_{il}|}{\sigma_l^3} + \frac{S_{il}^{1/\sigma_l}}{\sigma_l^2}, \\ I &= \frac{\frac{\partial}{\partial \alpha_l} \left(-\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right)}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} - \frac{\left(-\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right) \left(-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l} \right)}{\left(\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right) \right)^2} \\ &= \frac{\frac{1}{T_i \sigma_l^3} \left(\frac{S_{il}^{1/\sigma_l}}{\sigma_l} \log S_{il} + S_{il}^{1/\sigma_l} \right)}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} + \frac{\frac{S_{il}^{1/\sigma_l}}{T_i \sigma_l^3}}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} - \frac{\left(-\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right) \left(-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l} \right)}{\left(\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right) \right)^2}, \end{aligned}$$

which is bounded by

$$\begin{aligned} &\left| \frac{\frac{S_{il}^{1/\sigma_l} \log S_{il}}{T_i \sigma_l^4}}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} \right| + \left| \frac{\frac{2S_{il}^{1/\sigma_l}}{T_i \sigma_l^3}}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} \right| + \left| \frac{\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3}}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} \right| \cdot \left| \frac{-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l}}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} \right| \\ &\leq \left| \frac{\log S_{il}}{\sigma_l^3} \right| + \frac{2}{\sigma_l^2} + \left| \frac{\log S_{il} + \sigma_l}{\sigma_l^3} \right|. \end{aligned}$$

Next,

$$\begin{aligned} \left| \frac{\partial^2 \log g(T_i|X_i; \boldsymbol{\theta}, 1)}{\partial \sigma_l \partial \beta_l} \right| &= \left| X_{il} \cdot \left[\frac{\partial}{\partial \alpha_l} \frac{\left(-\frac{S_{il}^{1/\sigma_l} (\log S_{il} + \sigma_l)}{T_i \sigma_l^3} \right)}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} + \frac{\partial}{\partial \alpha_l} \frac{S_{il}^{1/\sigma_l} \log S_{il}}{\sigma_l^2} \right] \right| = |X_{il} \cdot (I + II)| \\ &\leq |X_{il}| \left(\left| \frac{\log S_{il}}{\sigma_l^3} \right| + \frac{2}{\sigma_l^2} + \left| \frac{\log S_{il} + \sigma_l}{\sigma_l^3} \right| + \frac{S_{il}^{1/\sigma_l} |\log S_{il}|}{\sigma_l^3} + \frac{S_{il}^{1/\sigma_l}}{\sigma_l^2} \right) \end{aligned}$$

Finally, we show the second order derivatives w.r.t. α_l and β_k . Recalling Eq.(6.4), we have for $l \neq k$

$$\begin{aligned} \left| \frac{\partial^2 \log g(T_i|X_i; \boldsymbol{\theta}, 1)}{\partial \alpha_l \partial \beta_k} \right| &\leq \left| \frac{\partial}{\partial \beta_k} \frac{-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l}}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} \right| + \left| \frac{\partial}{\partial \beta_k} \frac{S_{il}^{1/\sigma_l}}{\sigma_l} \right| \\ &= \left| \frac{\left(-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l} \right) \left(-\frac{1}{T_i \sigma_k^2} S_{ik}^{1/\sigma_k} X_{ik} \right)}{\left(\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right) \right)^2} \right| \leq \frac{|X_{ik}|}{\sigma_k \sigma_l} \end{aligned}$$

and for $l = k$

$$\begin{aligned} \left| \frac{\partial^2 \log g(T_i|X_i; \boldsymbol{\theta}, 1)}{\partial \alpha_l \partial \beta_l} \right| &= \left| \frac{\frac{1}{T_i \sigma_l^3} S_{il}^{1/\sigma_l} X_{il}}{\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right)} - \frac{X_{il} \left(-\frac{1}{T_i \sigma_l^2} S_{il}^{1/\sigma_l} \right)^2}{\left(\sum_{l=1}^L \left(\frac{1}{T_i \sigma_l} S_{il}^{1/\sigma_l} \right) \right)^2} - \frac{S_{il}^{1/\sigma_l} X_{il}}{\sigma_l^2} \right| \\ &\leq \frac{2|X_{il}|}{\sigma_l^2} + \left| \frac{S_{il}^{1/\sigma_l} X_{il}}{\sigma_l^2} \right|. \end{aligned}$$

Note that to show $\mathbb{E}\{(\log S_{il})^2\} < \infty$ is equivalent to show $\mathbb{E}\{(\log T_i)^2\} < \infty$. It follows by elementary calculation and the properties of Weibull density that

$$\begin{aligned} \mathbb{E}\{(\log T_i)^2\} &\leq \delta_i \sum_{l=1}^L \int_0^\infty (\log t)^2 \psi(t; \sigma_l, \alpha_l, X_{il}, \boldsymbol{\beta}_l) dt \\ &\quad + (1 - \delta_i) \sum_{l=1}^L \int_0^\infty (\log t)^2 \exp \left(-\left(\frac{t}{\exp(\alpha_l + X_{il}^\top \boldsymbol{\beta}_l)} \right)^{1/\sigma_l} \right) dt < \infty, \end{aligned}$$

and we obtain Eq.(6.2). \square

The next two lemmas are used for the proof of the asymptotic normality of the MLE for the parameters involved.

Lemma 6.5. *Under assumptions A1~A5,*

$$\sqrt{n} \frac{\partial}{\partial \boldsymbol{\theta}} \widehat{Q}_n(\boldsymbol{\theta}_0) \xrightarrow{d} \mathcal{N}(0, I(\boldsymbol{\theta}_0)).$$

Proof. Under assumptions A1~A5 and Eq.(6.1), we have $\mathbb{E} \left\{ \left| \frac{\partial}{\partial \boldsymbol{\theta}} \log g(T_i|X_i; \boldsymbol{\theta}_0, \delta_i) \right| \right\} < \infty$.

By the dominated convergence theorem,

$$\begin{aligned} \mathbf{0} &= \frac{\partial}{\partial \boldsymbol{\theta}} Q(\boldsymbol{\theta}_0) = \frac{\partial}{\partial \boldsymbol{\theta}} \mathbb{E} \{ \log g(T_i|X_i; \boldsymbol{\theta}_0, \delta_i) \} = \mathbb{E} \left\{ \frac{\partial}{\partial \boldsymbol{\theta}} \log g(T_i|X_i; \boldsymbol{\theta}_0, \delta_i) \right\} \\ &= \mathbb{E} \left\{ \frac{1}{n} \sum_{i=1}^n \frac{\partial}{\partial \boldsymbol{\theta}} \log g(T_i|X_i; \boldsymbol{\theta}_0, \delta_i) \right\} = \mathbb{E} \left\{ \frac{\partial}{\partial \boldsymbol{\theta}} \widehat{Q}_n(\boldsymbol{\theta}_0) \right\}. \end{aligned}$$

As the Fisher information matrix $I(\boldsymbol{\theta}_0)$ is well defined at $\boldsymbol{\theta}_0$, by central limit theorem and the proved Eq.(6.2), we obtain the result. \square

Lemma 6.6. *Under assumptions A1~A5, for any sequence $\tilde{\boldsymbol{\theta}}_n \xrightarrow{p} \boldsymbol{\theta}_0$,*

$$\frac{\partial^2}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^\top} \widehat{Q}_n(\tilde{\boldsymbol{\theta}}_n) + I(\boldsymbol{\theta}_0) \xrightarrow{p} 0$$

Proof. By assumptions A1~A4, we have all bounded first- and second-order derivatives, i.e., $\mathbb{E} \left\{ \left| \frac{\partial}{\partial \boldsymbol{\theta}} \log g(T_i|X_i; \boldsymbol{\theta}, \delta_i) \right| \right\} < \infty$ and $\mathbb{E} \left\{ \left| \frac{\partial^2}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^\top} \log g(T_i|X_i; \boldsymbol{\theta}, \delta_i) \right| \right\} < \infty$. Applying the dominated convergence theorem and Lemma 6.2 obtains that for any $\boldsymbol{\theta} \in \Theta$,

$$\frac{\partial^2}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^\top} \widehat{Q}_n(\boldsymbol{\theta}) \rightarrow \frac{\partial^2}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^\top} Q(\boldsymbol{\theta})$$

uniformly in probability. Further, it follows by assumption A5 that

$$\sup_{\boldsymbol{\theta} \in \Theta} \left| \frac{\partial^2}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^\top} \widehat{Q}_n(\boldsymbol{\theta}) - (-I(\boldsymbol{\theta})) \right| = \sup_{\boldsymbol{\theta} \in \Theta} \left| \frac{\partial^2}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^\top} \widehat{Q}_n(\boldsymbol{\theta}) - \frac{\partial^2}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^\top} Q(\boldsymbol{\theta}) \right| \xrightarrow{p} 0.$$

Then for any sequence $\tilde{\boldsymbol{\theta}}_n \xrightarrow{p} \boldsymbol{\theta}_0$, by the continuity of $I(\boldsymbol{\theta})$ at $\boldsymbol{\theta}_0$,

$$\begin{aligned} \left| \frac{\partial^2}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^\top} \widehat{Q}_n(\tilde{\boldsymbol{\theta}}_n) + I(\boldsymbol{\theta}_0) \right| &\leq \left| \frac{\partial^2}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^\top} \widehat{Q}_n(\tilde{\boldsymbol{\theta}}_n) + I(\tilde{\boldsymbol{\theta}}_n) \right| + \left| I(\boldsymbol{\theta}_0) - I(\tilde{\boldsymbol{\theta}}_n) \right| \\ &\leq \sup_{\boldsymbol{\theta} \in \Theta} \left| \frac{\partial^2}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^\top} \widehat{Q}_n(\boldsymbol{\theta}) + I(\boldsymbol{\theta}) \right| + \left| I(\boldsymbol{\theta}_0) - I(\tilde{\boldsymbol{\theta}}_n) \right| \xrightarrow{p} 0. \end{aligned}$$

□

Now, combining all the results and lemmas, we are ready to prove the consistency and asymptotic normality.

Proof of Theorem 3.1. Under assumptions A1, A2, and A3, Lemmas 6.1 and 6.3 hold, ensuring that all conditions in Lemma 6.4 are satisfied, thereby the consistency is proved.

Under assumptions A1~A5, the MLE $\widehat{\boldsymbol{\theta}}_n \xrightarrow{p} \boldsymbol{\theta}_0$. As $\boldsymbol{\theta}_0$ is in an interior point of Θ , by mean value theorem,

$$\frac{\partial}{\partial \boldsymbol{\theta}} \widehat{Q}_n(\widehat{\boldsymbol{\theta}}_n) - \frac{\partial}{\partial \boldsymbol{\theta}} \widehat{Q}_n(\boldsymbol{\theta}_0) = \frac{\partial^2}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^\top} \widehat{Q}_n(\tilde{\boldsymbol{\theta}}_n)(\widehat{\boldsymbol{\theta}}_n - \boldsymbol{\theta}_0),$$

where $\tilde{\boldsymbol{\theta}}_n$ lies on the segment between $\widehat{\boldsymbol{\theta}}_n$ and $\boldsymbol{\theta}_0$. Thus,

$$\frac{\partial}{\partial \boldsymbol{\theta}} \widehat{Q}_n(\boldsymbol{\theta}_0) + \frac{\partial^2}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^\top} \widehat{Q}_n(\tilde{\boldsymbol{\theta}}_n)(\widehat{\boldsymbol{\theta}}_n - \boldsymbol{\theta}_0) = 0,$$

where $|\widehat{\boldsymbol{\theta}}_n - \boldsymbol{\theta}_0| \leq |\tilde{\boldsymbol{\theta}}_n - \boldsymbol{\theta}_0| \xrightarrow{p} 0$ as $n \rightarrow \infty$. Applying Lemmas 6.5 and 6.6,

$$\sqrt{n}(\widehat{\boldsymbol{\theta}}_n - \boldsymbol{\theta}_0) = \left[-\frac{\partial^2}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^\top} \widehat{Q}_n(\tilde{\boldsymbol{\theta}}_n) \right]^{-1} \sqrt{n} \frac{\partial}{\partial \boldsymbol{\theta}} \widehat{Q}_n(\boldsymbol{\theta}_0) \xrightarrow{d} \mathcal{N}(0, I(\boldsymbol{\theta}_0)^{-1}).$$

□

Lemma 6.7 (Mill's ratio). *Let $h(t) = \exp\left(-\sum_{k=1}^L t^{1/\sigma_k} / \exp(\mu_k/\sigma_k)\right)$, $t > 0$. For large $M >$*

0 and $\sigma_* = \min(\sigma_1, \dots, \sigma_L)$, we have

$$\frac{h(M)}{\sum_{k=1}^L \zeta_k(M)} \left(1 - \frac{1/\sigma_*}{\sum_{k=1}^L M\zeta_k(M)} \right) \leq \int_M^\infty h(t) dt \leq \frac{h(M)}{\sum_{k=1}^L \zeta_k(M)} \left(1 + \frac{1}{\sum_{k=1}^L M\zeta_k(M) - 1} \right).$$

Proof. Recalling that for $h(t) = \exp\left(-\sum_{k=1}^L t^{1/\sigma_k} / \exp(\mu_k/\sigma_k)\right)$, the derivative

$$h'(t) = -h(t) \sum_{k=1}^L \frac{t^{1/\sigma_k - 1}}{\sigma_k \exp(\mu_k/\sigma_k)} =: -h(t) \sum_{k=1}^L \zeta_k(t),$$

where $\zeta_k(t) > 0, t > 0$, and $t \cdot \zeta_k(t) = t^{1/\sigma_k} / (\sigma_k \exp(\mu_k/\sigma_k))$ is a monotonically increasing function in $t > 0$. For the upper bound, we have for large $M > 0$,

$$\begin{aligned} \left(\sum_{k=1}^L M\zeta_k(M) - 1 \right) \int_M^\infty h(t) dt &\leq \int_M^\infty - \left(1 - \sum_{k=1}^L \frac{t^{1/\sigma_k}}{\sigma_k \exp(\mu_k/\sigma_k)} \right) h(t) dt \\ &= -t \cdot h(t) \Big|_M^\infty = M \cdot h(M), \end{aligned}$$

yielding that, for large $M > 0$ such that $\sum_{l=1}^M \zeta_k(M) > 1/M$

$$\int_M^\infty h(t) dt \leq \frac{h(M)}{\sum_{k=1}^L \zeta_k(M) - \frac{1}{M}} = \frac{h(M)}{\sum_{k=1}^L \zeta_k(M)} \left(1 + \frac{1}{\sum_{k=1}^L M\zeta_k(M) - 1} \right).$$

Next, we will show the lower bound. Recall $\sigma_* = \min(\sigma_1, \dots, \sigma_L)$, we consider

$$\begin{aligned}
& \left(1 + \frac{1/\sigma_*}{\sum_{k=1}^L M\zeta_k(M)} \right) \int_M^\infty h(t)dt \geq \int_M^\infty \left(1 + \frac{1/\sigma_*}{\sum_{k=1}^L t\zeta_k(t)} \right) h(t)dt \\
&= \int_M^\infty \left(1 + \frac{\frac{1}{\sigma_*} \sum_{k=1}^L t\zeta_k(t)}{\left(\sum_{k=1}^L t\zeta_k(t) \right)^2} \right) h(t)dt \geq \int_M^\infty \left(1 + \frac{\sum_{k=1}^L \frac{1}{\sigma_k} t\zeta_k(t)}{\left(\sum_{k=1}^L t\zeta_k(t) \right)^2} \right) h(t)dt \\
&= \int_M^\infty \left(1 + \frac{\sum_{k=1}^L \frac{1}{\sigma_k} \frac{\zeta_k(t)}{t}}{\left(\sum_{k=1}^L \zeta_k(t) \right)^2} \right) h(t)dt \geq \int_M^\infty \left(1 + \frac{\sum_{k=1}^L \left(\frac{1}{\sigma_k} - 1 \right) \frac{\zeta_k(t)}{t}}{\left(\sum_{k=1}^L \zeta_k(t) \right)^2} \right) h(t)dt \\
&= \int_M^\infty \frac{-h'(t) \sum_{k=1}^L \zeta_k(t)}{\left(\sum_{k=1}^L \zeta_k(t) \right)^2} + \frac{h(t) \sum_{k=1}^L \left(\frac{1}{\sigma_k} - 1 \right) \frac{\zeta_k(t)}{t}}{\left(\sum_{k=1}^L \zeta_k(t) \right)^2} dt = - \frac{h(t)}{\sum_{k=1}^L \zeta_k(t)} \Big|_M^\infty = \frac{h(M)}{\sum_{k=1}^L \zeta_k(M)}.
\end{aligned}$$

Thus,

$$\int_M^\infty h(t)dt \geq \frac{h(M)}{\sum_{k=1}^L \zeta_k(M)} \left(1 + \frac{1}{\sigma_* M \sum_{k=1}^L \zeta_k(M)} \right)^{-1} \geq \frac{h(M)}{\sum_{k=1}^L \zeta_k(M)} \left(1 - \frac{1}{\sigma_* M \sum_{k=1}^L \zeta_k(M)} \right)$$

using $1/(1+x) \geq 1-x$ for $x > 0$. We complete the proof of Lemma 6.7. \square

References

- Ahmad, F. B. and Anderson, R. N. (2021). The leading causes of death in the us for 2020. *Journal of the American Medical Association*, 325(18):1829–1830.
- Anderson, M. R., Cantu, E., Shashaty, M., Benvenuto, L., Kalman, L., Palmer, S. M., Singer, J. P., Gallop, R., Diamond, J. M., Hsu, J., et al. (2023). Body mass index and

- cause-specific mortality after lung transplantation in the United States. *Annals of the American Thoracic Society*, 20(6):825–833.
- Austin, P. C., Lee, D. S., and Fine, J. P. (2016). Introduction to the analysis of survival data in the presence of competing risks. *Circulation*, 133(6):601–609.
- Bandeem-Roche, K. and Liang, K.-Y. (2002). Modelling multivariate failure time associations in the presence of a competing risk. *Biometrika*, 89(2):299–314.
- Bellach, A., Kosorok, M. R., Rüschenhoff, L., and Fine, J. P. (2019). Weighted NPMLE for the subdistribution of a competing risk. *Journal of the American Statistical Association*, 114(525):259–270.
- Bishop, K., Moreno-Betancur, M., Balogun, S., Eynstone-Hinkins, J., Moran, L., Rao, C., Banks, E., Korda, R. J., Gourley, M., and Joshy, G. (2023). Quantifying cause-related mortality in Australia, incorporating multiple causes: observed patterns, trends and practical considerations. *International Journal of Epidemiology*, 52(1):284–294.
- Breger, T. L., Edwards, J. K., Cole, S. R., Saag, M., Rebeiro, P. F., Moore, R. D., and Eron, J. J. (2020). Estimating a set of mortality risk functions with multiple contributing causes of death. *Epidemiology*, 31(5):704–712.
- Buckley, J. and James, I. (1979). Linear regression with censored data. *Biometrika*, 66(3):429–436.
- Burns, A. and Iliffe, S. (2009). Alzheimer’s disease. *British Medical Journal*, 338(b158).
- Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020). Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. *The Lancet Neurology*, 19(11):951–962.
- Cui, Q., Xu, Y., Zhang, Z., and Chan, V. (2021). Max-linear regression models with regularization. *Journal of Econometrics*, 222(576–600).

- Cui, Q. and Zhang, Z. (2018). Max-linear competing factor models. *Journal of Business & Economic Statistics*, 36(1):62–74.
- Dempster, A. P., Laird, N. M., and Rubin, D. B. (1977). Maximum likelihood from incomplete data via the EM algorithm. *Journal of the Royal Statistical Society: series B (methodological)*, 39(1):1–22.
- Dobson, A., McElwee, P., Baneshi, M. R., Eynstone-Hinkins, J., Moran, L., and Waller, M. (2023). A new data driven method for summarising multiple cause of death data. *BMC Medical Research Methodology*, 23(1):83.
- Fine, J. P. and Gray, R. J. (1999). A proportional hazards model for the subdistribution of a competing risk. *Journal of the American Statistical Association*, 94(446):496–509.
- Gepp, A. and Kumar, K. (2015). Predicting financial distress: A comparison of survival analysis and decision tree techniques. *Procedia Computer Science*, 54:396–404.
- Goetghebeur, E. and Ryan, L. (1995). Analysis of competing risks survival data when some failure types are missing. *Biometrika*, 82(4):821–833.
- He, Y., Kim, S., Mao, L., and Ahn, K. W. (2022). Marginal semiparametric transformation models for clustered multivariate competing risks data. *Statistics in Medicine*, 41(26):5349–5364.
- Heagerty, P. J. and Zheng, Y. (2005). Survival model predictive accuracy and ROC curves. *Biometrics*, 61(1):92–105.
- Jennrich, R. I. (1969). Asymptotic properties of non-linear least squares estimators. *The Annals of Mathematical Statistics*, 40(2):633–643.
- Jeong, J.-H. and Fine, J. (2006a). Direct parametric inference for the cumulative incidence function. *Journal of the Royal Statistical Society Series C: Applied Statistics*, 55(2):187–200.

- Jeong, J.-H. and Fine, J. P. (2006b). Parametric regression on cumulative incidence function. *Biostatistics*, 8(2):184–196.
- Jin, Z., Lin, D., Wei, L., and Ying, Z. (2003). Rank-based inference for the accelerated failure time model. *Biometrika*, 90(2):341–353.
- Jin, Z., Lin, D., and Ying, Z. (2006). On least-squares regression with censored data. *Biometrika*, 93(1):147–161.
- Johansson, L. A. and Westerling, R. (2000). Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics. *International Journal of Epidemiology*, 29(3):495–502.
- Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., and Jones, D. T. (2021). Alzheimer disease. *Nature reviews Disease primers*, 7(1):33.
- Lai, T. L. and Ying, Z. (1991). Large sample theory of a modified Buckley-James estimator for regression analysis with censored data. *The Annals of Statistics*, 19(3):1370–1402.
- Lau, B., Cole, S. R., and Gange, S. J. (2009). Competing risk regression models for epidemiologic data. *American journal of epidemiology*, 170(2):244–256.
- LeBlanc, M., Moon, J., and Kooperberg, C. (2006). Extreme regression. *Biostatistics*, 7(1):71–84.
- Li, K., O’Brien, R., Lutz, M., Luo, S., Initiative, A. D. N., et al. (2018). A prognostic model of Alzheimer’s disease relying on multiple longitudinal measures and time-to-event data. *Alzheimer’s & Dementia*, 14(5):644–651.
- Li, Z., Wang, S., Liu, S., Gong, X., Wang, Y., Wu, D., Yang, M., Li, R., Li, H., Li, X., et al. (2022). Synergistic impact of diabetes and cognitive impairment on all-cause and cause-specific mortality in Chinese older adults: A prospective population-based cohort study. *Frontiers in Endocrinology*, 13:997260.

- Liu, Y., Xu, Y., Li, X., Chen, M., Wang, X., Zhang, N., Zhang, H., and Zhang, Z. (2024). Towards precision oncology discovery: four less known genes and their unknown interactions as highest-performed biomarkers for colorectal cancer. *NPJ Precision Oncology*, 8(1):13.
- Lo, S. M. and Wilke, R. A. (2010). A copula model for dependent competing risks. *Journal of the Royal Statistical Society Series C: Applied Statistics*, 59(2):359–376.
- Lu, K. and Tsiatis, A. A. (2001). Multiple imputation methods for estimating regression coefficients in the competing risks model with missing cause of failure. *Biometrics*, 57(4):1191–1197.
- Mao, L. and Lin, D. (2017). Efficient estimation of semiparametric transformation models for the cumulative incidence of competing risks. *Journal of the Royal Statistical Society Series B: Statistical Methodology*, 79(2):573–587.
- Miller, R. G. (1976). Least squares regression with censored data. *Biometrika*, 63(3):449–464.
- Moreno-Betancur, M. and Latouche, A. (2013). Regression modeling of the cumulative incidence function with missing causes of failure using pseudo-values. *Statistics in medicine*, 32(18):3206–3223.
- Moreno-Betancur, M., Sadaoui, H., Piffaretti, C., and Rey, G. (2017). Survival analysis with multiple causes of death: extending the competing risks model. *Epidemiology*, 28(1):12–19.
- Morris, H. R., Spillantini, M. G., Sue, C. M., and Williams-Gray, C. H. (2024). The pathogenesis of Parkinson’s disease. *The Lancet*, 403(10423):293–304.
- Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., and Beckett, L. (2005). The alzheimer’s disease neuroimaging initiative. *Neuroimaging Clinics of North America*, 15(4):869–877.
- Newey, W. K. and McFadden, D. (1994). Large sample estimation and hypothesis testing. *Handbook of Econometrics*, 4:2111–2245.

- Petersen, R. C. (2004). Mild cognitive impairment as a diagnostic entity. *Journal of Internal Medicine*, 256(3):183–194.
- Prentice, R. L., Kalbfleisch, J. D., Peterson Jr, A. V., Flournoy, N., Farewell, V. T., and Breslow, N. E. (1978). The analysis of failure times in the presence of competing risks. *Biometrics*, pages 541–554.
- Satagopan, J., Ben-Porat, L., Berwick, M., Robson, M., Kutler, D., and Auerbach, A. (2004). A note on competing risks in survival data analysis. *British Journal of Cancer*, 91(7):1229–1235.
- Schroeder, B. and Gibson, G. A. (2009). A large-scale study of failures in high-performance computing systems. *IEEE transactions on Dependable and Secure Computing*, 7(4):337–350.
- Tokdar, S. T. and Kass, R. E. (2010). Importance sampling: a review. *Wiley Interdisciplinary Reviews: Computational Statistics*, 2(1):54–60.
- Uno, H., Cai, T., Pencina, M. J., D’Agostino, R. B., and Wei, L.-J. (2011). On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. *Statistics in Medicine*, 30(10):1105–1117.
- Uno, H., Cai, T., Tian, L., and Wei, L.-J. (2007). Evaluating prediction rules for t -year survivors with censored regression models. *Journal of the American Statistical Association*, 102(478):527–537.
- Wijnen, A., Bishop, K., Joshy, G., Zhang, Y., Banks, E., and Paige, E. (2022). Observed and predicted premature mortality in Australia due to non-communicable diseases: a population-based study examining progress towards the WHO 25X25 goal. *BMC Medicine*, 20(1):57.
- Wu, C. F. J. (1983). On the convergence properties of the EM algorithm. *The Annals of Statistics*, 11(1):95–103.

- Xie, S.-H., Chen, H., and Lagergren, J. (2020). Causes of death in patients diagnosed with gastric adenocarcinoma in Sweden, 1970-2014: A population-based study. *Cancer Science*, 111(7):2451–2459.
- Zhang, Z. (2021). Five critical genes related to seven COVID-19 subtypes: A data science discovery. *Journal of Data Science*, 19(1):142–150.
- Zhang, Z. (2022a). The existence of at least three genomic signature patterns and at least seven subtypes of COVID-19 and the end of the disease. *Vaccines*, 10(5):761.
- Zhang, Z. (2022b). Genomic biomarker heterogeneities between SARS-CoV-2 and COVID-19. *Vaccines*, 10(10):1657.